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Melanoma is the most aggressive type of skin cancer with increasing incidence rates. To 
date, there are no effective therapies that can ensure disease free or even progression free 
survival of melanoma patients. While early stage primary melanoma is curable by surgical 
resection, survival of patients with metastatic melanoma is measured in months. Therefore it is of 
utmost importance to decipher molecular events that precede and/or induce the switch towards 
the invasive melanoma phenotype. In pursue of efficient therapy, attention has to be given not 
only to the cancer cells themselves but also to the microenvironment that nurtures and promotes 
malignant behavior. Aggressive melanoma cells drastically remodel their microenvironment. We 
found that expression of two extracellular matrix (ECM) proteins was significantly altered in 
melanoma compared to uninvolved patient skin: Tenascin C (TNC) was markedly increased, 
while small proteoglycan Decorin (DCN) was decreased. We found that invasion of the 
melanoma cells correlates with TNC expression levels and that cells present TNC 
asymmetrically at the invasive fronts. We also found that Epidermal Growth Factor-Like (EGFL) 
repeats of TNC promote melanoma cell invasiveness by activating Rho-associated kinase and 
increasing cell contractility, thus allowing mesenchymal to amoeboidal switch in mode of 
migration. Interestingly, TNC and DCN have both been shown to affect signaling through 
Epidermal Growth Factor receptor (EGFR), but with opposite outcomes on cell proliferation, 
migration and survival. We adapted skin organ cultures to test the influence of these two proteins 
Cues from the extracellular space: matrix proteins regulate melanoma invasion 
Jelena Grahovac, MS 
University of Pittsburgh, 2012.
 
 v 
on melanoma invasion and found that DCN can ameliorate TNC induced melanoma invasion. 
Taken together, our findings imply that ECM composition has a significant role in the regulation 
of melanoma invasiveness and that even in the presence of increased pro-invasive TNC signaling 
DCN can be a promising moiety for melanoma therapy. 
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1.0  INTRODUCTION 
More than half a million deaths from cancer are projected to occur in 2012 in United 
States (Siegel et al., 2012). Metastasis is responsible for 90% of cancer deaths and is the main 
factor for cancer treatment failure (Hanahan and Weinberg, 2000). Metastasis is a complex, 
multistage process in which cancer cells exit the primary tumor, survive in the circulation, seed 
the distant sites and grow. The non-malignant stromal cells and the extracellular matrix in the 
microenvironment influence each of these stages. Elucidating the means by which the 
microenvironment facilitates cancer progression may thus contribute to the development of new 
therapeutics, since targeting both tumor cells and stroma may give greater therapeutic success. 
Malignant melanoma is an excellent model for studying molecular changes associated with 
invasive and metastatic disease, in part due to its sequential step-by-step progression in which 
molecular changes can be attributed to each step of progression. Easy access to melanocytic 
lesions and melanoma on the body surface allows the establishment of hundreds of cell lines 
from different stages of the progression for the purposes of experimental studies, to an extent 
greater than in the case of any other cancer type (Berking and Herlyn, 2001) .  
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1.1 MELANOMA 
 Melanoma is the most aggressive type of skin cancer and its incidence is constantly 
increasing (Perlis and Herlyn, 2004).  It is predicted that in 2012 in the United States, melanoma 
will be diagnosed in 76250 patients with over 9000 deaths (www.cancer.gov). Melanoma is a 
significant public health problem and is a great scientific and medical challenge due to its 
heterogeneity and notorious chemotherapy resistance.  
1.1.1 Melanoma progression 
 Melanoma cells arise from transformed melanocytes, pigmented cells of neuroectodermal 
origin, that normally reside in the basal layer of the epidermis. In healthy skin the ratio of 
melanocytes to keratinocytes is approximately 1:5, and melanocyte homeostasis is regulated by 
keratinocytes by cell-cell contacts mediated by cadherins, through gap junctions and through the 
secretion of signaling molecules and growth factors (reviewed in (Santiago-Walker et al., 2009). 
Additionally, melanocytes are kept in place by integrin interaction with the basement membrane. 
The initial abnormal proliferation of melanocytes that is confined to the epidermis can show 
varying levels of dysplasia, but if left untreated all melanoma cells have the potential to invade 
and metastasize. In melanoma, melanocytes undergo E- to N- cadherin switch allowing them to 
escape keratinocyte control and establish contacts with fibroblasts and endothelial cells in the 
dermis (Haass et al., 2004) and alter integrin expression which allows their release from the 
basement membrane (reviewed in (Haass et al., 2005)). The majority of melanomas go through a 
linear progression: from benign nevi to dysplasia to the radial growth phase (RGP) melanoma 
that spreads laterally in the epidermis, and further to the vertical growth phase (VGP) melanoma, 
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which invades into the dermis and has the ability to metastasize, reaching the final step- 
metastatic melanoma (Figure 1) (Clark et al., 1984).   
 
Figure 1.  Stages of the melanoma progression. 
 
The adequate surgical resection of RGP melanoma has a high cure rate, but VGP primary 
melanomas have multiple genetic abnormalities and are able to grow independently of 
exogenous growth factors, to invade and metastasize. Patients with VGP and MGP melanoma 
have very poor survival rates. Therefore, it is of crucial importance to elucidate the events that 
lead to the progression from RGP to VGP melanoma. 
To date, there are no good predictive markers for either melanoma progression or the 
clinical outcome. Melanoma tumors have a very heterogeneous composition, consisting of cells 
with varying malignant potential, display various antigens and are able to secrete a variety of 
cytokines and growth factors (Elias et al., 2010a). In addition, melanomas metastasize to 
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multiple organs and their biological behavior is different from one site to another. Its variability 
and unpredictability have greatly limited treatment of melanoma, with surgery as the only 
effective modality of treatment in all types (Elias et al., 2010b).  
1.1.2 Current therapy for melanoma 
In general, melanoma does not show significant response to chemotherapy. In addition to 
taxanes and platinum agents the-FDA approved drugs for advanced melanoma are: Dacarbazine 
– an alkylating and DNA cross-linking agent, Yervoy (Ipilimubab) - a monoclonal antibody 
targeting T-lymphocyte antigen CTLA-4, Zelboraf (Vemurafenib) - a BRAF inhibitor that blocks 
V600E mutated BRAF protein and Adesleukin – recombinant analog of interleukin 2 
(www.cancer.gov). Two most recently developed drugs, approved in 2011: Yervoy, which helps 
turn back on the anticancer immune response and Zelboraf, which can be used only in patients 
carrying the most common mutation in melanoma - V600E BRAF, have unusually severe side 
effects (including fatal autoimmune reaction and squamous cell carcinoma, respectively) but 
prolong survival. 
Currently, there are no available therapies capable of ensuring a disease-free, or even a 
progression-free survival of melanoma patients. Targeting a single pathway will not be sufficient 
to eradicate melanoma. The interaction of melanoma cells with the surrounding stroma strongly 
influences the transformation and progression processes, and taking into account the complexity 
of the melanoma microenvironment, should help devise more effective therapeutic regimens. 
This was recently confirmed by a study in which Dacarbazine treatment was more effective in 
patients in whom the drug could also induce stromal remodeling in addition to the effects on 
melanoma tumor cells (Nardin et al., 2011). New treatment strategies have to take into account 
 5 
the microenvironment, since specific components in the extracellular tumor space provide 
signals for the invasion and progression of tumor cells and could serve as therapeutic targets.  
1.2 TUMOR MICROENVIRONMENT 
The cellular microenvironment contributes significantly to normal cellular function as 
well as to tumor development, growth and spread. The malignant phenotype of tumors is 
dependent not only on the intrinsic changes in cancer cells but also on the interactions of non-
cancer stromal cells, secreted factors and extracellular matrix (ECM) network that together make 
up the tumor microenvironment. Remodeled tumor microenvironment resembles the changes 
observed during embryogenesis, including cell plasticity, migration, vasculogenesis and 
angiogenesis.    
Melanoma is composed of melanoma tumor cells and stoma, which includes resident 
fibroblasts and endothelial cells, infiltrated immune cells, soluble factors and ECM. Aggressive 
melanoma cells remodel the microenvironment, and in turn, the modified microenvironment has 
a notable influence on the phenotype both of melanoma cells themselves and of the surrounding 
stromal cells (Hendrix et al., 2003). Even normal melanocytes can be shifted to invasive 
behavior by exposure to melanoma-produced ECM (Seftor et al., 2005). In addition, melanoma 
cells that leave the primary tumor site can induce molecular signals in the microenvironment for 
other tumor cells to follow, since melanoma cells can express endothelial-associated markers and 
form tubular structures that mimic vasculogenic networks (Maniotis et al., 1999). 
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1.2.1 Cells in the tumor stroma 
Stromal cells can influence cancer cell behavior by secreting chemokines, cytokines, 
growth factors, proteases, protease inhibitors and various ECM proteins; and they create a 
permissive environment for tumorigenesis. The most abundant cell type in solid tumors are 
fibroblasts (Allen and Louise Jones, 2011) that have a functional role in tumor development 
since they can promote angiogenesis, proliferation and survival of tumor epithelial cells and can 
even induce tumorigenesis in non-tumorigenic epithelial cells  (Hu and Polyak, 2008a; Olumi et 
al., 1999). In melanoma, following E- to N-cadherin switch, cancer cells establish 
communication with fibroblasts through gap junctions (Hsu et al., 2000). Additionally, by 
producing TGF-β, bFGF and PDGF melanoma cells induce rapid proliferation of fibroblasts, and 
in turn, fibroblasts produce a series of growth factors that support melanoma growth (Hsu et al., 
2002; Li et al., 2003; Li et al., 2009). Melanoma-derived TGF-β activates fibroblasts to produce 
the matrix with a high expression of collagens, Fibronectin and Tenascin C (Berking et al., 
2001), and the invasiveness of melanoma correlates with the ability to stimulate the stromal host 
fibroblasts (Li et al., 2009). Furthermore, melanoma-associated fibroblasts interfere with natural 
killer cells’ function and thus have an immunosuppressive role (Balsamo et al., 2009). 
In addition to the previously postulated six hallmarks of cancer (Hanahan and Weinberg, 
2000), inflammation has recently been proposed to be the seventh hallmark (Colotta et al., 2009). 
Inflammatory cells are recruited to reorganize the tumor stroma and macrophages form a major 
population in most solid tumors. Macrophage infiltration correlates with the progression of 
melanoma, and macrophage-derived cytokines induce the production of potent angiogenic 
factors, such as VEGF and IL-8 by melanoma cells, thus promoting angiogenesis (Torisu et al., 
2000). The number of tumor-infiltrating lymphocytes also increases with the melanoma 
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progression (Hussein et al., 2006). Neutrophils, macrophages and mast cells are the source of 
matrix metalloproteinase (MMP)-9 in aggressive skin tumors (Coussens et al., 2000) and the 
production of MMPs by stromal and infiltrating tumor cells greatly contributes to the progression 
of melanoma by both destruction of the ECM and by modulating the immune response. There is 
also a possible correlation between the presence of mast cells and the pathogenesis of primary 
melanoma (Dyduch et al., 2011). 
Both cancer-associated fibroblasts (CAFs) and macrophages remodel the existing ECM 
during the tumor progression by releasing extracellular proteases (Egeblad and Werb, 2002), but 
CAFs  also generate the altered ECM environment by secreting a different profile of ECM 
proteins compared to their normal counterparts (Allen and Louise Jones, 2011). Cancer subtypes 
with different clinical outcomes have recently been identified on the basis on the ECM-gene 
related profiles (Bergamaschi et al., 2008). 
1.2.2 Extracellular matrix 
 In normal physiological conditions extracellular matrix provides the structural support for 
tissues and organs, for layers of cells in the form of the basement membrane and for individual 
cells as substrate for migration. It also provides signals for the basic cell functions and serves as 
a reservoir for biologically active molecules. In vertebrate genomes there are hundreds of genes 
coding ECM proteins. Some are ancient and present in all Metazoa, like type IV collagens, 
laminins, Nidogen, Perlecan and collagens XV/XVII which compose the basement membrane, 
while the novel ones, like tenascins and fibronectins have evolved more recently (reviewed in 
(Hynes, 2009)). The human matrisome (all the components of the extracellular matrix) accounts 
for around 4% of the human proteome. In addition to 43 known collagen genes, the human 
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genome encodes 200 ECM glycoproteins and 35 proteoglycans (Naba et al., 2012). In general, 
ECM molecules are classified as fiber-forming, such as collagen and elastin, or interfibrillar 
which are the majority of proteoglycans and glycoproteins (Jarvelainen et al., 2009). ECM 
proteins are typically large, composed of several protein domains that are specialized for protein 
interactions and ECM assembly, or for the recruitment of other proteins (such as growth factors) 
and cells to the ECM (Hynes, 2012).  They are often non- and enzymatically linked and are 
mostly insoluble, which makes their analysis challenging.   
 After changes in cell-cell adhesion, the remodeling of the ECM plays a critical role in 
tumor invasion. Both tumor and stromal cells contribute to these changes and tumors of differing 
metastatic potentials differ in both the tumor- and the stroma-derived components (Naba et al., 
2012). In melanoma, production of ECM is drastically altered; there is an increase in the 
production of collagens, Tenascin C, SPARC and certain laminins and an isoform shift and 
increase in Fibronectin I expression (Hood et al., 2010; Ilmonen et al., 2004; Ledda et al., 1997; 
Natali et al., 1995; Pyke et al., 1994). Recent proteomic characterization of the extracellular 
matrix of human melanoma xenografts in mice has revealed the origin of certain ECM 
components (Naba et al., 2012): Fibronectin I, Collagen IV and Nidogen in the tumor stroma 
were secreted by both tumor and stromal compartments equally; Collagen I and III were secreted 
by both but with greater stromal contribution, which was the case with Tenascin C in more 
invasive tumors, while in less invasive ones the contribution was equal. Detected Vitronectin, 
Decorin and Collagen XIV were solely of stromal origin, while the tumor cells secreted certain 
laminins and latent growth factor binding proteins. Matrix components secreted by the tumor 
cells varied significantly with their metastatic potential, and the matrisome secreted by stromal 
compartment changed in response to the potential of tumor cells indicating a profound cross-talk 
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between tumor and stromal cells. Summary of described melanoma-stromal interactions is 
depicted in Figure 2. 
 
Figure 2.  Melanoma-stromal cell interactions through growth factors, cytokines 
and ECM. 
It has been suggested that the progression of tumors to malignancy is controlled by the 
microenvironment which provides tumor-suppressive signals (Bissell and Hines, 2011); by 
modifying the ECM composition cancer cells are altering the architecture and homeostasis of the 
tissue and releasing their malignant potential.  
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1.3 MATRIKINES 
The concept of matrikines has been proposed in order to define protein domains from the 
ECM which can signal to the surrounding cells (Maquart et al., 1999). Some of these signals can 
be provided by cryptic sites within the ECM molecules that are revealed only after the structural 
or conformational alteration (Davis et al., 2000). In the course of tissue injury or tumor invasion, 
matrix alterations due to ECM denaturation, enzymatic breakdown, mechanical forces or protein 
multimerization and adsorption, provide a plethora of matrycriptis signals. In recent years, 
special attention was given to a class of matrikines that are able to signal through growth factor 
receptors (Tran et al., 2005). These matrikines posses low binding affinity for growth factor 
receptors but are often present in high valence, which increases the avidity for the receptor and 
enables efficient signaling. So far, these domains were found in Collagen, Laminin, Decorin and 
Tenascin C and they enable persistent non-degradable signals (Tran et al., 2004). Interestingly, 
analysis of melanoma tissue samples and adjacent uninvolved skin of the same patient revealed 
that the expression of two matrikines Tenascin C and Decorin is opposite, and inversed 
compared to the expression in the normal human skin (Hood et al., 2010)(Figure 3). 
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Figure 3.  Proteomic analysis of human melanoma tissue sample and uninvolved 
skin of the same patient. 
(A) Schematic outline of the proteomic analysis procedure (image courtesy of Drs 
Thomas Conrads and Brian Hood) (B) Table representing ECM protein counts in melanoma and 
normal skin. Numbers represent the number of peptides detected out of 10000 analyzed peptides 
per sample. 
 
1.3.1 Tenascin C 
The physiological role of Tenascin C (TNC) lies in establishing of the interactions 
between the epithelium and the mesenchyme during embryonic development, tissue 
differentiation and wound repair; therefore expression of TNC is transient and strictly regulated 
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(Jones and Jones, 2000b). Persistent high levels of TNC are present in various tumor tissues, 
including brain, bone, prostate, intestine, lung, skin, and breast (Pas et al., 2006). During 
development TNC is expressed along the pathways of neural crest migration (Mackie et al., 
1988), and given that melanocytes are derived from the neural crest, the expression of TNC in 
melanomas might be a reactivation of a developmental pathway as many of the processes leading 
to transformation of melanocytes are reminiscent of differentiation stages during development.  
Tenascin C is a hexameric glycoprotein composed of 180 to 320 kDa monomers, which 
are disulfide-linked at their N-termini (Figure 4). Different molecular weights of TNC are the 
consequence of glycosylation and alternative splicing. Each subunit contains: the N-terminal 
assembly domain, a domain composed of 14.5 EGF-like repeats, a domain composed of 
fibronectin type III-like (FNIII) repeats and a fibrinogen-like sequence on the C terminus 
(Aukhil et al., 1993; Chiquet-Ehrismann and Chiquet, 2003; Erickson and Bourdon, 1989; Jones 
and Jones, 2000a; Orend, 2005; Orend and Chiquet-Ehrismann, 2006). Modular structure of 
TNC enables interactions with various binding partners that can have different functions during 
tissue injury and tumorigenesis. TNC can interact with several other ECM proteins and cell 
surface receptors thus influencing tissue architecture and cell response.  
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Figure 4.  Schematic illustration of TNC monomer and hexamer.  
 
The Fibronectin III (FNIII)-like domain of TNC is the site of interaction with 
Fibronectin, Heparin, Perlecan, Aggrecan, Versican and Brevican (Midwood and Orend, 2009), 
and the hexameric structure of TNC may allow cross-linking of ECM molecules and re-
organization of the matrix architecture. Cells can interact with the FNIII-like domain of TNC via 
integrins α2β1, α7β1, α9β1, αVβ1, αVβ3, and αVβ6, which allow cell attachment, and via 
syndecans-1 and -4, and annexin II which can signal de-adhesion (reviewed in (Midwood and 
Orend, 2009; Orend and Chiquet-Ehrismann, 2006)). Therefore, the response to TNC differs 
depending on the receptor repertoire present on the cell surface. TNC can be alternatively spliced 
within the FNIII-like repeats (designated by letters A to D) and the most represented isoform in 
tumor tissues is the full length 320 kDa, although different splice variants can co-exist in the 
same tumor tissue (Pezzolo et al., 2011). It is not clear whether alternatively spliced forms have 
clearly distinct roles, but the presence of the FNIIIA-D repeats is responsible for some anti-
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adhesive and pro-proliferative properties of TNC (Chung et al., 1996; Huang et al., 2001; 
Murphy-Ullrich et al., 1991). TNC can promote de-adhesion of cells adhered on Fibronectin 
(FN) (Chiquet-Ehrismann et al., 1988); and this de-adhesion can be signaled by TNC 
interference with FN binding to Syndecan-4, and preventing the FN induced cell spreading 
(Huang et al., 2001); or through one of the known receptors for TNC - Annexin II, calcium 
binding membrane protein, which binds TNC through alternatively spliced A-D fibronectin III-
like domain. Only the variants containing the he whole A-D domain can bind and signal de-
adhesion via Annexin II (Chung et al., 1996).  
Epidermal Growth Factor-like (EGFL) repeats of TNC also have counter-adhesive 
properties (Prieto et al., 1992; Spring et al., 1989) and have been shown to bind and signal 
through the Epidermal Growth Factor receptor (EGFR) (Iyer et al., 2007a; Swindle et al., 2001). 
The affinity of select EGFL repeats for EGFR is in the micromolar range (Swindle et al., 2001) 
but the matrix-constrained environment that limits diffusion and hexameric presentation of the 
repeats within the TNC molecule allow high avidity of the binding (Iyer et al., 2007a). 
Furthermore, the binding of TNC EGFL repeats does not induce receptor internalization, 
restricting EGFR signaling to the plasma membrane, which preferentially activates the EGFR 
pro-migratory signaling cascade: the activation of phospholipase C γ involved in lamellipod 
protrusion formation, and the activation of m-calpain involved in tail retraction during cell 
migration (Iyer et al., 2008). 
Fibrinogen-like globe of TNC binds to αVβ3 integrin (Yokoyama et al., 2000) and Toll-
like receptor 4 (TLR4) and exhibits pro-inflammatory effects by the activation of Toll-like 
receptors in macrophages and fibroblasts (Midwood et al., 2009).  
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In summary, TNC is equipped not only to modulate ECM architecture but also to 
dramatically influence the behavior of cells. TNC expression in tumors can be induced by 
various inflammatory cytokines and growth factors that are mostly secreted by stromal cells: 
TNFα, IFNγ, IL-1, -4, -6, -8, -13, EGF and TGFβ, just to name a few (reviewed in (Chiquet-
Ehrismann and Chiquet, 2003)). In addition, reactive oxygen species, hypoxia and mechanical 
stress, which are all present in the tumor tissue, can induce TNC expression (reviewed in 
(Midwood and Orend, 2009)). TNC can be cleaved by MMPs and serine proteases, and some of 
these events can reveal cryptic sites. For example, MMP2 cleavage of TNC occurs after the 
second alternatively spliced FNIII domain (Siri et al., 1995)  and reveals a cryptic adhesive site 
in the FNIII domain that binds to Syndecan-4 and causes β1 integrin activation (Saito et al., 
2007).  Cleavage sites for MMP2, MMP3, MMP7 and MMP9 are all within the FNIII like 
domain or the NH2 terminal knob, leaving EGFL repeats intact (Siri et al., 1995). TNC itself 
induces the expression of MMPs 1, 3, and 9 (Tremble et al., 1994) and activation of MMP2; in 
addition, TNC deposition is positively regulated by MMP3 and MMP9 (Dang et al., 2004). 
Consequently, there is a positive feedback loop between induction of MMPs by TNC and its 
cleavage.  
In normal human skin TNC is expressed at low levels in papillary dermis beneath the 
basal lamina, within the walls of blood vessels and around sweat glands (Lightner et al., 1989) 
and it comprises only 0.02-0.05% of total protein in papillary dermis. Upon photo damage of the 
skin TNC can be detected throughout the epidermis, at the epidermal-dermal junction and deep 
in papillary dermis (Filsell et al., 1999). It is upregulated in wounded skin (Latijnhouwers et al., 
1996) being produced by keratinocytes in the early phases of the wound healing (Latijnhouwers 
et al., 1997) and co-localizes with lymphocyte infiltration in inflamed dermis (Seyger et al., 
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1997). TNC peaks at the end of the inflammatory phase of tissue repair and promotes tissue 
rebuilding, and the levels return to normal after the repair is complete (Betz et al., 1993).  The 
upregulation of TNC in melanoma is an example that supports the hypothesis that “tumors are 
the wounds that never heal” (Dvorak, 1986) as in the tumor microenvironment constant high 
levels of TNC are present, produced both by transformed tumor cells and stromal cells (De 
Wever et al., 2004; Hanamura et al., 1997; Yoshida et al., 1997). In vitro, the majority of human 
melanoma cell lines secrete TNC (Herlyn et al., 1991) and the expression levels of TNC in 
melanoma cell lines derived from tumors of different stages correlate with the severity of the 
stage (Figure 14). Thus, an open question remains whether the TNC expressed by the melanoma 
cells can drive melanoma progression. TNC has been shown to be important for the proliferation 
of melanoma cells when they are grown as spheres, suggesting its role in the maintenance of 
tumor initiating cells (Fukunaga-Kalabis et al., 2010). In melanoma tumor tissue, TNC seems to 
be incorporated in channel-like structures together with Fibronectin and pro-Collagen I 
(Kaariainen et al., 2006) and it is suggested that these structures can form a continuum between 
avascular and vascular tumor tissue and can serve as the scaffold for tumor angiogenesis 
(Midwood et al., 2011). It has also been proposed that cancer cells are the main source of TNC in 
micrometastases until the stroma takes over and becomes the primary source in larger metastases 
(Oskarsson et al., 2011). The growth of melanoma tumors in TNC knock-out mice is suppressed 
compared to the wild type due to the lack of TNC from the stroma, which is needed for VEGF 
expression and tumor vascularization (Tanaka et al., 2004). It is likely that TNC plays several 
roles in tumor progression, and that the endogenous TNC synthesized by tumor cells and stroma-
derived TNC have both overlapping and distinct roles. The underlying signal transduction 
pathways responsible for TNC pleiotropic effects are mostly unknown. 
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1.3.2 Decorin 
 Decorin (DCN) is the small (40kDa) leucine-rich proteoglycan synthesized chiefly by 
stromal fibroblasts, endothelial cells under stress and smooth muscle cells (Neill et al., 2012). 
Decorin contains a protein core and a single chondroitin/dermatan sulfate glycosaminoglycan 
chain attached to a serine near the N terminus (Chopra et al., 1985) (Figure 5) . It is mostly found 
in collagen–rich connective tissues (Bianco et al., 1990) where it interacts with high affinity with 
collagen fibers and is involved in collagen fibrologenesis (Danielson et al., 1997; Keene et al., 
2000; Zhang et al., 2006). In addition, DCN can bind to multiple growth factor receptors 
including EGFR (Iozzo et al., 1999b), Met receptor (Goldoni et al., 2009) and IGF-1R (Iozzo et 
al., 2011). DCN can also sequester TGFβ family members into the extracellular matrix, as there 
are two binding sites for TGFβ in the DCN core (Hildebrand et al., 1994). 
 
 
Figure 5.  Schematic illustration of Decorin. 
 
The first identified receptor tyrosine kinase to bind Decorin was EGFR (Iozzo et al., 
1999b): DCN initially triggers receptor activation, dimerization and internalization, but 
prolonged exposure induces EGFR down-regulation (Zhu et al., 2005) thus terminating EGFR 
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signaling. The affinity of DCN is in the nanomolar range (70nM) (Santra et al., 2000; Santra et 
al., 2002) comparable to the EGF itself, and the binding site of DCN within the EGFR is partially 
overlapping but distinct from the EGF binding site (Santra et al., 2002). DCN is also an 
antagonist of the Met receptor (Goldoni et al., 2009) and can inhibit the PDGF receptor (Merline 
et al., 2011). Therefore, DCN can be considered an endogenous matrix-centric pan-kinase 
inhibitor (Neill et al., 2012) and along with TGFβ sequestering function which leads to tumor 
immunosupression and growth retardation, has been proposed  to be “a guardian from the 
matrix” to draw a comparison to “guardian of the genome” p53 (Neill et al., 2012). Notably, the 
cooperation between Decorin and p53 has already been established (Iozzo et al., 1999a). 
In normal human skin Decorin is produced by fibroblasts, with higher expression in 
deeper dermis compared to the superficial layers (Honardoust et al., 2012). Quiescent fibroblasts 
are the main source of DCN, as proliferating fibroblasts produce significantly lower levels 
(Mauviel et al., 1995). The disruption of Decorin leads to abnormal collagen fibril morphology 
and skin fragility (Danielson et al., 1997). DCN is a vital player in maintaining the overall 
integrity of the skin by both providing structural organization and indirect signaling (Reed and 
Iozzo, 2002).  In melanoma, Decorin can be found in peritumoral stroma, but not in melanoma 
cells or dense tumor tissue (Brezillon et al., 2007). 
Interestingly, Decorin and Tenascin C, two ECM proteins with opposing roles in tumor 
progression share two receptors TLR 4 and EGFR. TNC can bind to TLR 4 via its fibrinogen 
domain (Midwood et al., 2009) and soluble Decorin was also found to bind to TLR 2 and TLR4 
on macrophages thus boosting their inflammatory activity and suppressing tumor growth 
(Merline et al., 2011). The EGFL repeats of TNC and the leucine rich domain of DCN can 
activate the same receptor – EGFR without sharing structural homology. In addition, TNFα and 
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TGFβ1 can down-regulate DCN expression (Mauviel et al., 1995), and TGFβ1 is being secreted 
by melanoma cells and is up-regulating TNC expression (Berking et al., 2001). In melanoma 
TNC and DCN proteins have inversed expression (Figure 24), which makes it interesting to 
postulate that one can counteract the other in the melanoma extracellular matrix setting. 
1.4 THE ROLE OF THE EXTRACELLULAR MATRIX IN TUMOR CELL 
ADHESION AND MIGRATION 
1.4.1 Cell-matrix adhesion 
 The adhesion of cells to the extracellular matrix is important for basic cell functions: it is 
necessary for the cell growth, survival, differentiation and cell migration. On rigid two- 
dimensional substrates cell adhesion is three-phasic: cells first attach to the substratum, then they 
spread, and in the last phase they form focal adhesions and stress fibers (Figure 6). The initial 
attachment is mediated by integrins and their ECM substrates and is weak in strength; next, with 
the appropriate signals from the ECM the cells increase the surface area of the contact with the 
substratum and spread through the formation of actin microfilaments. The clustering of integrins 
and their activation then induces formation of focal adhesions and strengthens the adhesion. This 
whole process is reversible and upon appropriate intra- or extracellular signals during cell 
proliferation, motility or morphogenesis, cells can de-adhere to various extents.  
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Figure 6.  Stages of cell adhesion on two-dimensional substratum. 
 
Much less is known about the process of de-adhesion in which the cell moves to a state of 
weaker adherence. The state of weaker adherence can be induced by the matricellular proteins 
Thrombospondin-1 and -2, Tenascin C and SPARC (reviewed in (Murphy-Ullrich, 2001)). These 
proteins function both in soluble and insoluble states and can promote only initial stages of cell 
adhesion – attachment and spreading. When presented with other matrix proteins they can 
antagonize adhesive activities of these other molecules (Adams and Schwartz, 2000; Murphy-
Ullrich and Hook, 1989; Wenk et al., 2000) and when added as soluble agents they can disrupt 
focal adhesion complexes of already spread cells (reviewed in (Orend and Chiquet-Ehrismann, 
2000)).  
 Adhesive proteins can also gain anti-adhesive properties under certain conditions: MMP2 
cleavage of Laminin-5 can expose a cryptic anti-adhesive and pro-migratory site in the α2 chain 
(Giannelli et al., 1997) and the same enzyme can cleave Fibronectin and release its anti-adhesive 
site that competes with the native Fibronectin (Watanabe et al., 2000). Little is known about the 
signaling mechanisms that are being activated by the adhesion modulatory ECM proteins, but the 
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change in cell shape and the reorganization of the actin cytoskeleton are the major common 
determinants. The major candidate class for the actin cytoskeleton remodeling are integrins, 
heterodimeric transmembrane receptors, which mediate cell attachment to ECM and link it to the 
cytoskeleton (Giancotti and Ruoslahti, 1999).   
 In melanoma, cell matrix interactions shift from Collagen IV and Laminin adhesion in 
normal melanocytes to Collagen I and Vitronectin in melanoma cells, in addition to the cadherin 
switch that allows melanoma cell detachment from keratinocytes. Increased and altered 
expression profiles of integrin combinations that are important for the progression of melanoma 
are: αVβ3 that binds to Fibronectin, Fibrinogen, Von Wildebrand factor, certain collagens, 
Thrombospondin-1, Osteopontin, Laminin and Tenascin C; αvβ1 that binds Fibronectin, 
Vitronectin and Tenascin C and α5β1 that binds Fibronectin ((Albelda et al., 1990; Felding-
Habermann et al., 1992; Natali et al., 1997; Natali et al., 1993; Van Belle et al., 1999) and 
reviewed in (van der Flier and Sonnenberg, 2001)). αVβ3 is especially important for melanoma 
survival in 3D collagen environment (Montgomery et al., 1994).  
1.4.2 Cell migration 
 The intermediate state of cell adhesion favors motility (DiMilla et al., 1991; DiMilla et 
al., 1993). Matricellular proteins that promote the intermediate state of adhesion have increased 
expression at the exact sites of remodeling that require cell migration - during embryogenesis, 
wound healing, inflammation and tumor invasion. This suggests a role for the matricellular 
proteins in promoting migration by enabling the intermediate adhesive state. A mathematical 
model developed by DeMilla, Barbee and Lauffenburger predicts that the maximal motility of 
cells is achieved when the ratio of the cellular force, achieved through cytoskeletal contractility, 
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and the adhesive strength, achieved through integrin-matrix interactions, is intermediate (DiMilla 
et al., 1991). Weak cell adhesion does not generate enough force for the cell movement, and too 
strong adhesion prevents the releasing of the cell from the ECM (Palecek et al., 1997). Migration 
requires the coordination of the cell extension, adhesion/de-adhesion and contraction, and is 
simultaneously regulated by growth factors and the ECM molecules. 
In order for cells to move, the existing adhesion sites have to be disassembled and the 
new ones have to be formed. Current understanding of cell-matrix adhesions and migration is 
based mostly on in vitro studies on rigid 2D surfaces that induce an artificial polarity between 
lower and upper cell surfaces. In vivo, cells are embedded within 3D matrices and focal 
adhesions differ from classically described in vitro adhesions in structure, localization and 
functions (Cukierman et al., 2001). Both three-dimensionality and the composition of the matrix 
are contributing to more effective mediation of the adhesion and enhanced migration of cells in 
vivo or in in vivo-like 3D matrix compared to mechanically 2D flattened cell matrix, or 
individually presented matrix components in 2D (Cukierman et al., 2001).  
In order to move during tumor invasion in vivo, cancer cells must break away from the 
primary tumor mass and deform and/or degrade the ECM. Contrary to the 2D motility that is 
based on actin polymerization that propels the cell forward, in 3D environment the force of 
protrusive actin polymerization drives cells into spindle shaped mesenchymal morphology that 
can allow cell migration only in the presence of proteases that degrade the surrounding ECM 
(Sahai and Marshall, 2003; Wolf et al., 2003). A hallmark of tumor cell invasion is upregulation 
of proteolytic enzymes generated both by migrating cells and the stromal cells (Kessenbrock et 
al., 2010). Proteolytic mesenchymal migration is a multi step process. The cell polarization and 
initial protrusion are followed by the attachment of the leading edge to ECM. Next, the cell 
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surface localized degradation of ECM generates space into which actomyosin contraction will 
move the advancing cell body deforming both the cell and the ECM. Finally, retraction of the 
cell rear and turnover of adhesions occur (Friedl and Wolf, 2010; Wolf and Friedl, 2011). 
However, in 3D context tumor cells can also invade without the requirement for the proteolytic 
activity and move through ECM without its degradation by acquiring a rounded morphology and 
using actin contractile force to generate amoeboid bleb-like protrusions that push and squeeze 
cells through the ECM (Friedl, 2004; Sahai and Marshall, 2003; Wolf et al., 2003; Wyckoff et 
al., 2006). Migration is possible in the absence of proteolysis if both the porosity of the matrix 
and the cell body deformability can support it. Molecular and structural characteristics of both 
tissue microenvironment and cell behavior determine whether cells will migrate collectively or 
individually in mesenchymal or amoeboid mode. ECM stiffness, fiber orientation, density and 
gap size provide parameters that modulate cell adhesion and cytoskeletal organization (Friedl 
and Wolf, 2010). In 3D stiff matrices mesenchymal migratory force generation is β1 integrin-
dependent (Wolf et al., 2003) while soft matrices do not reinforce focal adhesion formation and 
support cell rounding (Ulrich et al., 2009). While mesenchymal migration is dependent on 
alternative pushing and pulling cycles, amoeboidal migration is equally mechanically complex 
and combines stronger pushing with less adhesive pulling of the substrate (Friedl and Wolf, 
2010). The tuning model proposed by Friedl and co-workers predicts that cell migration is a 
continuum of states that are determined by several modal parameters that simultaneously control 
how cell migrates and that their combined magnitudes impact which migrational mode the cell 
will adopt (Friedl and Wolf, 2010). A central signaling pathway that controls the conversion 
between mesenchymal and rounded migration is the balance between Rac and Rho signaling 
(Sahai and Marshall, 2003). 
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1.4.3 Molecular mechanisms of mesenchymal and amoeboid migration 
 The Rho family of small GTPases is the key regulator of both cell adhesion and 
cytoskeleton during cell migration. The most studied members of the family are Cdc42, Rac1 
and RhoA. In the mesenchymal mode of migration, formation of actin-rich filopodia and 
lamellipodia is Cdc42- and Rac1-dependent (Nobes and Hall, 1995; Ridley and Hall, 1992; 
Ridley et al., 1992). Cdc42 and Rac regulate WASP/WAVE proteins that promote the nucleation 
of actin filaments and the formation of the leading edge (Miki et al., 1998; Rohatgi et al., 1999). 
The protruding leading edge is then stabilized by integrin interactions with the ECM and the 
formation of focal adhesions. Rho and its downstream effector Rho-associate kinase (ROCK) 
have been shown to be dispensable for the mesenchymal mode of migration (Sahai and Marshall, 
2003), where Cdc42 can compensate the loss of Rho/ROCK signaled contractility (Wilkinson et 
al., 2005). In contrast, the rounded mode of motility is dependent on Rho and ROCK activity 
(Sahai and Marshall, 2003), where ROCK-dependent myosin light chain (MLC) phosphorylation 
is crucial for the correct organization of MLC and force generation within the moving cell 
(Wyckoff et al., 2006). Phosphorylated MLC increases ATPase activity to promote actin-myosin 
interactions and contractile force generation. The intracellular pressure results in the rupture of 
the actomyosin cortex and the formation of membrane blebs (Keller and Eggli, 1998). After the 
formation of the bleb the contractile cortex reassembles (Charras et al., 2006). One major 
difference between mesenchymal and amoeboid movement is therefore the driving force for the 
formation of protrusions, which are actin polymerization and cytoplasm inflow, respectively. The 
silencing of ROCK pathway induces the transition from amoeboidal to mesenchymal 
invasiveness (Sahai and Marshall, 2003; Sanz-Moreno et al., 2008) and the silencing of Rac 
induces the opposite shift (Sanz-Moreno et al., 2008; Yamazaki et al., 2009). In addition, active 
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Rac negatively regulates Rho/ROCK signaling (Sander et al., 1999) and inhibits cell rounding, 
while active Rho/ROCK limits Rac activity that inhibits cell extension (Sanz-Moreno et al., 
2008). Mesenchymal and amoeboid cell phenotypic characteristics and possible signaling 
controls are summarized in Figure 7. 
 
Figure 7.  Mesenchymal and amoeboid cell phenotypes. 
 
Rho proteins are often overexpressed in tumors (Fritz et al., 1999) and one of the key 
events in experimental melanoma metastasis is the upregulation of RhoC (Clark et al., 2000). 
The inhibition of RhoC or the combined inhibition of RhoA and ROCK1/2 greatly reduce 
melanoma invasion (Sahai and Marshall, 2003; Wolf et al., 2003). In melanoma, genes involved 
in the control of cell motility show altered expression levels, but not mutational activation 
(Gaggioli and Sahai, 2007), as activation of one step but not the others in the migration process 
would give un-coordinated and inefficient motility. Two modes of migration are interchangeable 
and arise as a reply to the specifics of the microenvironment (Pankova et al., 2010). So far, apart 
from the influence of the collagen fiber spatial organization (Provenzano et al., 2008), little is 
 26 
known about the ECM components that influence the migratory shifts or the cellular receptors 
that signal them. 
1.5 MODELS FOR IN VITRO STUDY OF MELANOMA INVASION 
One of the obstacles in developing effective therapeutic approaches for melanoma is the 
lack of good experimental models that recapitulate the in vivo behavior of tumors. Biological 
properties of 2D cultured melanoma cells only partially resemble those in situ. Melanoma 
development is a result of deregulated signaling between melanocytes, keratinocytes and the 
stroma, and has to be studied in the context of multicellular 3D environment. As melanocyte 
regulation by keratinocytes is very intricate, studying melanoma progression requires the 
organotypic models that would include as many players as possible. The goal is to recreate the 
characteristics of the tumor in the appropriate microenvironmental context. Rodent models of 
melanoma have not proven to be successful in recapitulating the early stages of melanoma 
invasion since melanocytes are localized differently in rodent and human skin and rodents do not 
develop spontaneous melanoma.  
 A key feature of signaling from the ECM is the spatial organization of cells within 
tissues, such that the cell shape, spacing and positioning within the 3D structure are additional 
factors in cell response to signals. Therefore, it is of importance to study cell migration and 
invasion in matrices with the models that would most resemble the natural occurrence of these 
proteins. In vivo cells experience the surrounding ECM as a three dimensional network, and this 
cannot be mimicked in two dimensional cell culture assays.  
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1.5.1 Skin organ constructs 
Skin organ constructs (SOC) are the most advanced in vitro models for the study of 
melanoma-microenvironment interactions and present a link between two-dimensional cultures 
and in vivo models. These cultures are composed of dermal and epidermal equivalents. Dermal 
equivalents can be made by repopulating post mortem acquired de-cellularized human dermis 
with fibroblasts (Ghosh et al., 1997; Regnier et al., 1986), or by embedding primary fibroblasts 
into collagen gels and letting them contract and remodel the gel (Bell et al., 1983; Marionnet et 
al., 2006). Seeding primary keratinocytes on top of dermal equivalents forms epidermis. Gradual 
withdrawal of EGF from the culture medium induces keratinocyte differentiation. Placing gels 
on top of rafts and exposing them to air allows keratinization of the epidermis resembling 
stratum corneum. Keratinocytes can generate normal epidermis irrespective of the species origin 
of fibroblasts which allows identification of the origin of the components involved in tissue 
reconstitution (Stark et al., 2004). These organotypic models form the basement membrane and 
the epidermal-dermal junction is straight in the case of dermal collagen gels (Meier et al., 2000b; 
Smola et al., 1998), or follows natural ridges in de-cellularized human dermis. Both 
keratinocytes and fibroblasts contribute to the formation of the basement membrane in SOC and, 
interestingly, TNC is present during formation of the dermal-epidermal junction (Marionnet et 
al., 2006). If melanocytes are included in the model, they migrate and position themselves at the 
basal levels of the epidermis and make contacts to multiple keratinocytes (Valyi-Nagy et al., 
1990).  Melanoma cells from different stages of progression can be incorporated into SOCs and 
they reflect the characteristics of the cells in situ: RGP cells do not invade into dermis, while 
VGP and MGP derived cells invade (Meier et al., 2000b). The representative images of SOCs 
made from contracted collagen gels grown at the air liquid interface are shown in the Figure 8. 
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Figure 8.  Skin organ constructs. 
(A) SOC composed of fibroblast-contracted collagen gel seeded with keratinocytes is shown in 
the left side panel, and SOC with melanoma cells seeded on top of the epidermis is shown on the 
right. Arrow points to the mole-like growth of melanoma cells expressing GFP that were initially 
seeded within a cloning ring on top of the epidermis. (B) H&E staining of SOCs. The 
arrowheads point to non-invading and invading melanoma tumors, respectively; scale bar 
100µm. E-epidermis, D-dermis, M-melanoma. 
 
These cultures are suitable for use of transfected and infected cells and are a useful tool 
for studying protein function in melanoma progression. Genetic perturbations of melanoma cells 
sometimes show drastic differences in growth compared to control cells that were otherwise 
undetectable in 2D culture systems (Hsu et al., 1998; Satyamoorthy et al., 2001). For example, 
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SOCs were used to show that αVβ3 integrin up-regulation induces conversion from RGP to VGP 
melanoma and progressive invasion (Hsu et al., 1998). Skin organ reconstructs are healthy for up 
to a month in culture and biological phenotype of melanoma cells is remarkably stable (Meier et 
al., 2000b). Quantification of invasion in SOCs can be achieved by taking into account both the 
depth and the pattern of invasion (Nystrom et al., 2005). In addition, these cultures can be grafted 
on immunodeficient mice for long-term studies (Javaherian et al., 1998). 
1.6 HYPOTHESIS 
 Given the significant change in the composition of the extracellular matrix in invasive 
melanomas compared to normal skin counterparts, we reasoned that distinct de-regulated ECM 
proteins could drive the melanoma cell invasion. We hypothesize that the increased expression of 
ECM protein Tenascin C by melanoma cells themselves can drive melanoma invasion by 
increasing migration of cells in 3D environments. We postulate that this pro-invasive effect of 
TNC would be mapped to the EGFL repeats of TNC, as these were shown to activate the pro-
migratory EGFR signaling cascade (Iyer et al., 2008). Furthermore, we hypothesize that another 
EGFR-binding matrikine, Decorin, could counteract TNC-driven melanoma invasion. In this 
work we will first test whether skin organ cultures seeded with melanoma cells can recapitulate 
changes in the ECM found in human melanoma samples and then test the influence of Tenascin 
C and Decorin on modulating melanoma invasion. 
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2.1 ABSTRACT 
Gaining insights into the molecular events that govern the progression from melanoma in 
situ to advanced melanoma, and understanding how the local microenvironment at the melanoma 
site influences this progression, are two clinically pivotal aspects that to date are largely 
unexplored. In an effort to identify key regulators of the crosstalk between melanoma cells and 
the melanoma-skin microenvironment, primary and metastatic human melanoma cells were 
seeded into skin organ cultures (SOCs), and grown for two weeks. Melanoma cells were 
recovered from SOCs by laser microdissection and whole-cell tryptic digests analyzed by 
nanoflow liquid chromatography-tandem mass spectrometry with an LTQ-Orbitrap. The 
differential protein abundances were calculated by spectral counting, the results of which 
provides evidence that cell-matrix and cell-adhesion molecules that are upregulated in the 
presence of these melanoma cells recapitulate proteomic data obtained from comparative 
analysis of human biopsies of invasive melanoma and a tissue sample of adjacent, non-involved 
skin. This concordance demonstrates the value of SOCs for conducting proteomic investigations 
of the melanoma microenvironment. 
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2.2 INTRODUCTION 
Despite increasing efforts aimed at melanoma prevention and, equally important, early 
detection, the worldwide incidence of melanoma continues to rise. As there are no effective 
treatment regimens for patients with advanced melanoma, the molecular basis of melanoma 
progression is likely to hold the key to clinical treatment. Melanoma progression is a 
pathologically well-defined process and when surgically resected with a wide and deep margin, 
the prognosis for patients with melanoma in situ is favorable. While melanoma in situ is confined 
to the epidermis, primary melanoma in the vertical growth phase (VGP) has invaded deep into 
the dermis and, unlike melanoma in situ but like melanoma in the metastatic growth phase 
(MGP), VGP melanoma proliferates aggressively.  
Over the past few years, high-throughput studies such as serial analysis of gene 
expression (SAGE), whole-genome microarray expression profiling and integrative analysis by 
microarray-based comparative genomic hybridization (array-CGH) have led to the identification 
of genes that previously were not known to be expressed in advanced melanomas, and/or were 
found to be upregulated with progression from early to advanced-stage melanoma. More 
recently, mass spectrometry (MS)-based proteomics has been used to identify proteins that are 
differentially expressed in VGP versus MGP melanomas (Baruthio et al., 2008), or to detect 
melanoma in its early stage of development (Caron et al., 2009; Forgber et al., 2009; Paulitschke 
et al., 2009). Unlike in the case of breast cancer, however, where various high-throughput 
molecular approaches have generated significant information detailing the interactions among 
epithelial and stromal cells that play supporting roles in tumorigenesis (Hu and Polyak, 2008b), 
little information is yet available regarding the contributions of the local microenvironment to 
melanoma invasion and progression.  
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The epidermis is a multilayered structure, which is separated by an intact basement 
membrane from mesenchymal support cells. The stem cell-like basal keratinocytes undergo 
asymmetric replications with a multi-cell vertical differentiation resulting in enucleation and 
formation of a keratinized barrier. Neuroectoderm-derived melanocytes migrate into and reside 
in the epidermis where they are in contact with and communicate through E-cadherin and 
connexin junctions with keratinocytes. As part of the invasion process, melanoma cells must 
transit an E-cadherin-bridged epithelial milieu, attach to and breach the laminin/fibronectin-rich 
basement membrane and penetrate the dermis to reach conduits for dissemination, such as the 
host vasculature (Fig. 9A). 
Detailed insights are lacking regarding how the local microenvironment affects or alters 
molecular features of melanoma cells that may be required to drive invasion and progression, 
arising from the absence of suitable skin models that mimic invasive growth. Indeed, rodent skin 
does not recapitulate the structural microenvironment of human skin and other animal models, 
such as porcine, do not present naturally occurring melanomas. Ex vivo human skin organ 
cultures (SOCs; Fig. 9B) have been used to investigate various human skin conditions including 
wound healing and have been used in a limited fashion in melanoma research (Eves et al., 2003; 
Eves et al., 2000; Herlyn et al., 2001; Meier et al., 2000a; Neil et al., 2000). Skin organ cultures 
are derived from excess pathological specimens obtained during cosmetic surgery or post 
bariatric weight loss, or can be generated ex vivo from human skin components (Margulis et al., 
2005).  
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Figure 9.  Melanoma model. 
(A) Stages of melanoma progression in skin. Melanocytes reside in the epidermal/dermal 
junction. Early stage radial growth phase melanoma cells descend into the papillary dermis and 
spread laterally. Invasion deep into the dermis characterizes melanomas in the vertical growth 
phase. (B) Skin organ culture (SOC). SOCs are maintained at the air-liquid interface. (Inset) 
Hematoxylin and eosin stained section collected on day 12 of culture. 
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In the present study, we demonstrate that seeding VGP and MGP melanoma cells into 
SOCs leads to formation of melanoma nodules after approximately 12 days. Laser micro-
dissection was utilized to acquire the melanoma tumor nodule from these tissue sections, as well 
as samples from collagen-injected and non-injected SOCs, which were analyzed by nano-flow 
liquid chromatography-tandem mass spectrometry (LC-MS/MS). An analysis of differential 
protein abundances by spectral counting was conducted, and demonstrates that the proteomic 
profiles very closely resemble that obtained from a differential proteomic analysis of human 
melanoma and an adjacent skin biopsy free of melanoma. These data suggest that melanoma-
seeded SOCs represent a unique model system for investigating the molecular events in the 
microenvironment that promote melanoma invasion and progression.  
2.3 RESULTS AND DISSCUSION 
The impact of the microenvironment on the expression of proteins that govern invasion 
and progression of melanoma is one of the fundamental, but yet largely unresolved questions 
regarding this malignancy. To gain a better understanding of the underlying molecular events 
involved in this process, the study presented here served to determine whether an in vitro skin 
organ culture system can recapitulate protein abundance differences between melanoma cells and 
surrounding skin of melanoma and adjacent non-involved skin tissue samples as identified by a 
differential proteomic analysis. The SOCs were injected with either VGP (WM983A) or MGP 
(WM1158) melanoma cell lines, or collagen alone to serve as a control. These two melanoma 
cell lines are widely utilized and were selected solely to compare melanoma growth to normal 
(e.g. non-involved) skin in this SOC model and not to provide a detailed comparison of VGP 
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versus MGP. Approximately 10,000 cells were collected by laser micro-dissection from these 
FFPE SOC sections (Fig. 10A). The micro-dissected cells were processed using an “MS-
friendly” heat-induced, enzyme-mediated (HI/EM) antigen retrieval method, followed by trypsin 
digestion (Fig. 10B). Peptide digests were analyzed by LC-MS/MS; Figure 10C shows a 
representative base peak chromatogram of a digest from approximately 5,000 cells on column 
from the micro-dissected FFPE VGP melanoma SOC section. This analysis afforded the 
identification of upwards of several hundred proteins per sample at a false discovery rate of 
approximately 2%, with all samples processed in duplicate.  
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Figure 10.  Mass spectrometry-based proteomic analysis of melanoma and skin organ 
cultures. 
(A) Hematoxylin and eosin staining of formalin-fixed, paraffin-embedded (FFPE) skin organ 
culture (SOC) sections injected with approximately 10 000 VGP melanoma cells (WM983A) 
before (left panel) and after (right panel) laser microdissection. (B) Laser microdissected FFPE 
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tissue samples were processed using a heat-induced, enzyme-mediated digestion protocol for 
LC-MS/MS analysis. (C) Base peak chromatogram of approximately 5000 VGP melanoma cells 
obtained by laser micro-dissection from the FFPE SOC tissue sections. 
 
Differences in protein abundance between the various SOC-derived samples were derived 
by spectral counting, where it was found that proteins such as Tenascin C (TNC) and 
Fibronectin, which have been described in the literature to play a role in melanoma cell invasion 
(Fukunaga-Kalabis et al., 2008; Kaariainen et al., 2006), were identified by high spectral count in 
the MGP melanoma SOC sections, and at lower levels in the VGP melanoma SOC sections 
(Table 1). 
 
Table 1. Spectral count data for selected extracellular matrix and cytoskeletal proteins identified 
in melanoma-injected or control SOCs and from melanoma and normal human skin tissue 
 
Skin organ cultures Biopsy  
Protein 
 
Function WM1158 WM983A collagen ctrl melanoma normal 
Tenascin C Matrix 19 7 1 0 143 0 
Fibronectin Adhesion/Matrix 11 6 0 0 46 20 
Collagen 1 Matrix 17 8 6 10 15 107 
α-Actinin-4 Adhesion/Cytoskeleton 2 1 0 0 76 22 
Thrombospondin-1 Adhesion/Matrix 2 2 0 0 4 1 
Plectin Adhesion/Cytoskeleton 17 1 0 1 153 15 
Transgelin 2 Adhesion/Cytoskeleton 6 0 0 0 14 18 
Cytokeratin 5 Adhesion/Cytoskeleton 69 9 30 31 43 9 
Cytokeratin 14 Adhesion/Cytoskeleton 56 1 22 13 25 14 
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Cytokeratin 6A Adhesion/Cytoskeleton 41 6 26 30 17 0 
Cytokeratin 16 Adhesion/Cytoskeleton 17 0 7 5 11 0 
Cytokeratin 17 Adhesion/Cytoskeleton 22 0 5 4 1 0 
 
These proteins were either not identified or were identified at very low abundance in the 
collagen and non-injected SOC controls. Increases in the abundance of TNC have been 
documented in MGP melanomas, and it has been suggested that relatively low levels of TNC 
expression may be associated with a lower risk for metastasis (Ilmonen et al., 2004). Like TNC, 
Fibronectin is another protein implicated in melanoma invasion. Specifically, it has been 
reported that these two proteins stimulate the invasive features of primary melanoma cells in 3D 
collagen matrices, and that TNC, Fibronectin and pro-collagen I form specific channel structures 
for melanoma invasion (Kaariainen et al., 2006). Tenascin C and Fibronectin are produced not 
only by fibroblasts, but also by endothelial cells and keratinocytes (Jones and Jones, 2000a). 
However, it is not yet fully established to what extent these proteins are also produced by VGP 
and/or MGP melanoma cells. The data presented here document that melanocytes, propagated in 
vitro, do not produce detectable levels of TNC (Fig. 11) and only low levels of Fibronectin (data 
not shown). In contrast, both MGP and VGP melanoma cells express substantial amounts of 
these matrix proteins. These matrix components are not only secreted but also incorporated into 
an insoluble matrix surrounding the cells, likely giving rise to the apparent difference in the 
relative levels of TNC transcript versus protein abundances measured in this study. The 
important point regarding this finding is that these melanoma cells produce these matrix 
components which are known to drive cell migration and tumor invasion (Iyer et al., 2007b).  
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Figure 11.  Expression of Tenascin C in melanoma cells. 
(A) Quantitative RT-PCR analysis of the expression of Tenascin C (TNC) mRNA in WM983A 
(VGP) and WM1158 (MGP) melanoma cells compared to human melanocytes, propagated in 
vitro. The data are expressed as the mean (standard deviation from three independent 
experiments. (B) Immunoblot analysis depicting the level of TNC in the VGP and MGP 
melanoma cell lines and melanocytes. (C) Immunofluorescence analysis of melanocytes and 
VGP and MGP melanoma cell lines, probed with antibody to TNC (pseudocolored green) and 
actin (pseudocolored red). The cells were counterstained with fluorescent DAPI (pseudocolored 
blue). 
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α-Actinin-4 (ACN4) is another protein identified as differentially abundant between the 
SOC melanoma samples and controls. Furthermore, as depicted in Figure 12, this protein is 
clearly present at higher levels in melanoma cells compared to melanocytes, both at the level of 
the transcript and protein. α-Actinin-4 is an actin cytoskeleton filament bundling protein and 
plays crucial roles in cell migration and cytokinesis (Sjoblom et al., 2008). In addition, growth 
factor signaling is important for dynamic control of ACN4/actin filament interactions, which in 
turn regulates cell adhesion during substratum attachment and nuclear segregation during mitosis 
(Shao et al., 2009). 
 
Figure 12.  Alpha-actinin-4 expression in melanoma cells. 
(A) Quantitative RT-PCR analysis of α-actinin-4 (ACN4) expression in the WM983A (VGP) and 
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WM1158 (MGP) melanoma cell lines and in melanocytes. The data are expressed as the mean 
(standard deviation from three independent experiments. (B) Immunoblot analysis of ACN4 
expression in the VGP and MGP melanoma cell lines and in melanocytes. (C) 
Immunofluorescence analysis of melanocytes and VGP and MGP melanoma cell lines, probed 
with antibody to ACN4 (pseudocolored green) and actin (pseudocolored red). The cells were 
counterstained with fluorescent DAPI (pseudocolored blue). 
 
The increased expression of both TNC and ACN4 was verified by immunohistochemistry 
(IHC) in WM983A injected SOCs in the region of the tumor lesion as compared to the collagen-
injected controls (Fig. 13). As expected, TNC appears to be localized to the extracellular space 
(Fig. 13A) whereas ACN4 expression is primarily observed to be intracellular (Fig. 13C). While 
low levels of TNC can be observed in the collagen-injected SOC, this observation likely arises 
from the fact that these skin cultures are immature and composed of neonatal fibroblasts and 
keratinocytes, both of which produce TNC. 
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Figure 13.  Immunohistochemical analysis of Tenascin C and α-actinin-4 in SOCs. 
Immunohistochemical analysis of the expression of Tenascin C (TNC) (A and B) and α-actinin-4 
(ACN4) (C and D) in SOCs injected with WM983A melanoma cells (A and C) compared to 
collagen injection controls (B and D). 
 
Thrombospondin-1 (TSP-1) was identified with an elevated abundance in both the MGP 
and VGP SOC sections compared to the controls. TSP-1 is a secreted protein that plays a role in 
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tissue remodeling, is upregulated in response to injury and inflammation (Bornstein, 2001) and 
has been detected at elevated levels in sera of patients with advanced melanoma (Bornstein, 
2009; Rofstad and Graff, 2001; Sid et al., 2004). Plectin was also substantially more abundant in 
the MGP melanoma cells than in the VGP melanoma cells. Plectin, a structural protein found in 
nearly every cell type, interacts with numerous cytoskeletal components and has a role in the 
interactions of intracellular junctions and contributes to tissue integrity (Svitkina et al., 1996; 
Wiche, 1989). Plectin has been shown to be upregulated in pancreatic and colon cancer (Bausch 
et al., 2009; Lee et al., 2004), but there are no reports that cite this protein as being expressed in 
advanced melanomas. Similar to Tenascin C and Fibronectin, Plectin was identified with an 
increased relative abundance in the melanoma tissue sample as compared to that of the normal 
skin sample.  
Alpha-enolase and pyruvate kinase M2 were identified with elevated abundances in the 
MGP SOC section relative to the other SOC samples. Increased levels of α-enolase have been 
previously associated with tumor cell migration and metastasis (Liu and Shih, 2007) and have 
been shown to be elevated in several metastatic melanoma cell lines (Nawarak et al., 2009; 
Rodeck et al., 1991). This increased expression level of α-enolase and pyruvate kinase M2 may 
reflect the apparent increased utilization of glycolysis for ATP generation in tumor cells as 
suggested by Warburg (Warburg et al., 1970). 
There are a number of notable proteins identified in the present study that merit further 
investigation. Of these, transgelin 2, a homolog of transgelin and member of a family of actin-
binding proteins that is proposed to be involved in cytoskeletal cross-linking and polymerization, 
was identified in greater relative abundance in the MGP SOC tissue section as compared to the 
other samples. There are several reports citing an upregulation of transgelins in gastric (Huang et 
 45 
al., 2008) and colorectal (Zhang et al., 2009) cancers. Transgelin has been shown to be involved 
with ERK-related signal transduction, however, the function of transgelin in cancer development 
and progression remains to be elucidated. The cytokeratin (CK) pairs 5/14 and 6/16 and 17 were 
observed with decreased abundances in the VGP SOC section. It is well known that cytokeratins 
play a significant role in the organization and integrity of cellular structure and are indicators for 
differentiation state and metastatic nature of tumor cells. A previous study established 
diminished expression levels of CK 5/14 and 6/16 and 17 in metastatic melanoma (Riker et al., 
2008). The present analyses also reveal an apparent increase in the abundance of pulmonary 
surfactant protein D in the VGP SOC section. While its role in melanoma has not been fully 
explored, the gene encoding this protein has been shown to be induced in a variety of metastatic 
pulmonary and non-small cell lung cancers, and is detectable in a variety of others, such as 
gastric, pancreas and prostate (Betz et al., 1995).  
2.4 CONCLUSIONS 
The findings of these proteomic analyses establish the feasibility of using SOCs for 
evaluating the tumor microenvironment and the changes in the molecular events that drive 
invasion and progression of melanoma. Melanoma cell lines, representing VGP and MGP 
melanoma, injected into SOCs demonstrate the ability to perform a differential proteomic 
analysis using a spectral count approach and generation of proteomic profiles which very closely 
resemble those obtained from an analysis of differential protein abundances from melanoma and 
normal skin biopsy tissues. Indeed, several known melanoma-related proteins, such as Tenascin 
C and Fibronectin, were identified at different relative abundances in the SOCs, which directly 
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correspond to the abundance differences observed in the analysis of the tissue biopsy samples. 
These data suggest that melanoma-seeded SOCs represent a unique model system to gain further 
insight regarding proteins that support melanoma cell invasion and the crosstalk between 
melanoma cells and the skin microenvironment.  
2.5 MATERIALS AND METHODS 
2.5.1 Cell cultures and tissue samples 
Normal human epidermal melanocytes (FC-0019, Lifeline Cell Technology, 
Walkersville, MD) were maintained in DermaLife Basal Medium with LifeFactors (LM-0027, 
Lifeline Cell Technology). The VGP (WM983A) and MGP (WM1158) human melanoma cell 
lines were propagated in vitro as described (Becker et al., 1989). De-identified, post-diagnosis, 
excess pathological specimens, representing an advanced melanoma and an adjacent skin biopsy 
with no clinical signs of melanoma, resected from a patient, were obtained in compliance with a 
University of Pittsburgh Cancer Institute (UPCI) and University of Pittsburgh Institutional 
Review Board (IRB)-approved protocol.  
2.5.2 Antibodies and reagents 
An anti-human/mouse Tenascin C monoclonal antibody (MAB2138) was purchased from 
R&D Systems (Minneapolis, MN), and mouse anti-α-actinin-4 antibody (sc-49333) was from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies were used at a 1:200 dilution for 
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immunoblotting and immunocitochemistry. For immunohistochemistry stainings, anti-human 
Tensacin C mouse monoclonal antibody (ab6393) and anti-human/mouse α-actinin 4 antibody 
(ab32816, Abcam, Cambridge, MA) were used at the final concentration of 2 µg/ml. 
2.5.3 Skin organ cultures 
Skin organ culture experiments were performed on human Epiderm full-thickness 400 
(EFT-400) 3D skin-like structures obtained from MatTek Corporation (Ashland, MA). These 
constructs contain human-derived dermal fibroblasts and epidermal keratinocytes and utilize 
bovine collagen as the base for the dermal matrix. Cultures were maintained at the air-liquid 
interface and supplied every other day with maintenance medium (EFT-400-MM, MatTek). 
Cultures were injected intra-epidermaly with 10,000 melanoma cells (either WM983A or 
WM1158) resuspended in 3 µg/mL rat tail collagen (R&D Systems). Collagen-injection and non-
injected SOCs served as controls. On day 13 after injection, tissues were divided in half with a 
razor; one half was formalin-fixed and paraffin-embedded, and the other half was embedded in 
OCT and frozen in liquid nitrogen. This time point was chosen based on previous reports as 
sufficient time for growth of tumor-like structures within the SOC (Eves et al., 2000; Meier et 
al., 2000a). Furthermore, the SOC maintain structural integrity for throughout this time period 
but begin to degenerate upon further culture. Cells from defined regions were acquired by laser 
micro-dissection (Leica LMD 6000, Leica Microsystems, Inc., Bannockburn, IL) and collected 
in 40 µL of purified H2O in RNAase/DNAse-free microcentrifuge tubes.  
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2.5.4 FFPE sample preparation 
Samples were brought to 100 mM NH4HCO3, pH 8.4, 60% acetonitrile and incubated in a 
thermal cycler at 100 °C for 1 h, and thereafter at 65 °C for an additional 2 h. Samples were 
cooled to ambient temperature, followed by addition of 100 ng of modified porcine sequencing 
grade trypsin (Promega) and incubated for 16 h at 37 °C. Samples were vacuum-dried and 
desalted using PepClean desalting columns (Pierce) according to the manufacturer’s protocol. 
Eluted peptides were vacuum-dried and stored at -80 °C.  
2.5.5 Human melanoma biopsy sample preparation 
Cryopreserved melanoma and human skin samples were placed in a Petri dish containing 
phosphate-buffered saline (PBS) on wet ice and cut into small pieces with a scalpel. Tissues were 
transferred to microcentrifuge tubes, homogenized for 10 s, snap-frozen in liquid nitrogen and 
brought to ambient temperature. Tissue lysates were sonicated for 15 sec (50 Hz) and 
supernatant was collected by centrifugation (2000 x g, 10 min). Fifty µg of each protein lysate 
was resolved by 1D SDS-PAGE and each lane was cut into ten equivalent slices that were 
digested in-gel according to established protocols.(Wilm et al., 1996) Briefly, gel bands were 
destained in 50% acetonitrile in 50 mM NH4HCO3, pH 8.4 and vacuum-dried. Trypsin (20 
µg/mL in 25 mM NH4HCO3, pH 8.4) was added and samples were incubated on wet ice for 45 
min. The supernatant was removed and gel bands were covered with 25 mM NH4HCO3, pH 8.4 
and incubated at 37 °C overnight. Tryptic peptides were extracted with 70% acetonitrile, 5% 
formic acid, lyophilized to dryness and resuspended in 0.1% trifluoroacetic acid (TFA) prior to 
LC-MS/MS analysis.  
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2.5.6 Mass spectrometry analyses 
Skin organ culture tryptic digests were analyzed in duplicate by nanoflow reversed-phase 
liquid chromatography (LC)-MS/MS using a nanoflow LC (Dionex Ultimate 3000, Dionex 
Corporation, Sunnyvale, CA) coupled online to a linear ion trap MS (LTQ-XL, ThermoFisher 
Scientific, San Jose, CA). Human biopsy tissue tryptic digests were similarly analyzed on an 
LTQ-Orbitrap MS (ThermoFisher). Separations were performed using 75 µm i.d. x 360 o.d. x 15 
cm long fused silica capillary columns (Polymicro Technologies, Phoenix, AZ) slurry packed in 
house with 5 µm, 300 Å pore size C-18 silica-bonded stationary phase (Jupiter, Phenomenex, 
Torrance, CA).  
Following sample injection onto a C-18 trap column (Dionex), the column was washed 
for 3 min with mobile phase A (2% acetonitrile, 0.1% formic acid) at a flow rate of 30 µL/min. 
Peptides from the SOC tissue sections were eluted using a linear gradient of 0.33% mobile phase 
B (0.1% formic acid in acetonitrile)/minute for 130 min, then to 95% B in an additional 15 min, 
all at a constant flow rate of 200 nL/min. In the case of the melanoma and skin tissue samples, 
peptides were eluted using a linear gradient of 1% mobile phase B/minute for 40 min, then to 
95% B in an additional 10 min, all at a constant flow rate of 200 nL/min. Column washing was 
performed at 95% B for 15 min for all analyses, after which the column was re-equilibrated in 
mobile phase A prior to subsequent injections.  
For the SOC analyses, the MS was operated in data-dependent MS/MS mode in which 
each full MS scan was followed by seven MS/MS scans performed in the linear ion trap (LIT) 
where the seven most abundant peptide molecular ions were selected for collision-induced 
dissociation (CID), using a normalized collision energy of 35%. The human melanoma and 
normal skin tissue digests were analyzed using a high resolution (R=60,000 at m/z 400) full MS 
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scan conducted in the Orbitrap followed by tandem MS of the top five molecular ions in the LIT 
as described above. Data were collected over a broad precursor ion selection scan range of m/z 
375-1800 for the SOC analysis and m/z 350-1800 for the analysis of the human tissue samples. 
Dynamic exclusion was enabled for both MS analyses to minimize redundant selection of 
peptides previously selected for CID.  
2.5.7 Bioinformatic analysis 
 Tandem mass spectra were searched against the UniProt human protein database (11/09 
release) from the European Bioinformatics Institute (http://www.ebi.ac.uk/integr8), using 
SEQUEST (ThermoFisher Scientific). Additionally, peptides were searched for methionine 
oxidation with a mass addition of 15.9949 Da. Peptides were considered legitimately identified if 
they met specific charge state and proteolytic cleavage-dependent cross correlation scores of 1.9 
for [M+H]1+, 2.2 for [M+2H]2+ and 3.5 for [M+3H]3+, and a minimum delta correlation of 0.08. 
A false peptide discovery rate of approximately 2% was determined by searching the primary 
tandem MS data using the same criteria against a decoy database wherein the protein sequences 
are reversed (Elias and Gygi, 2007). Results were further filtered using software developed in-
house, and differences in protein abundance between the samples were derived by summing the 
total CID events that resulted in a positively identified peptide for a given protein accession 
across all samples (spectral counting) (Liu et al., 2004). The spectral count data were normalized 
for each protein accession by calculating the percent contribution of the spectral count values for 
each protein accession against the total number of peptides identified within a given sample 
(Patel et al., 2008). 
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2.5.8 Real-time PCR 
Total mRNA from the melanocytes and melanoma cell lines was isolated using an 
RNAeasy Mini Kit (Qiagen, Valencia, CA), and 1 µg of mRNA was reverse-transcribed into the 
corresponding first-strand cDNA with the Quantitect Transcription Kit (Qiagen). PCR reactions 
were performed on a MX3000P Real-Time PCR instrument (Stratagene, Agilent Technologies, 
Santa Clara, CA), using 1 µl of first-strand cDNA per reaction with Brilliant SYBR Green QPCR 
Master Mix (Stratagene). Primers (Integrated DNA Technologies, Coralville, IA) are listed in the 
Table 2:  
Table 2. Primers used in real time PCR  
 
 
 
cDNA Sequence of primers 
Tenascin C 
Forward 
Reverse 
 
5’-GAGGTCAACAAAGTGGAGGCA-3’ 
5’-GAGAGATTGAAGCTCTCGGGAG-3’ 
α-Actinin-4 
Forward 
Reverse 
 
5’-CATATCAGGGGAGCGGTT-3’ 
5’-GCAATAAAGTCCAGCGCT-3’ 
GAPDH 
Forward 
Reverse 
 
5’-GAGTCAACGGATTTGGTCGT-3’  
5’-TTCATTTTGGAGGGATCTCG-3’ 
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All experiments were performed in triplicate, fold-abundance changes in transcript levels 
were quantified by the ΔCt method and target gene expression was normalized to GAPDH. The 
VGP melanoma cell line, WM983A, was used as a reference. 
2.5.9 Immunoblotting and Immunostaining 
Cell lysates were obtained by snap-freezing, thawing, and vortexing in lysis buffer (50 
mM Hepes, pH 7.9, 0.4 M KCl, 0.5 mM EDTA, 0.1% NP-40, 10% glycerol) supplemented with 
1 mM sodium orthovanadate, 50 mM sodium fluoride and protease inhibitor cocktail set V 
(Calbiochem, EMD Chemicals, Gibbstown, NJ). Protein concentrations were determined by the 
BCA assay (Pierce, Rockford, IL), and 100 µg of total protein per sample was resolved by 1D 
SDS-PAGE. Samples were transferred to PVDF membranes (Millipore, Billerica, MA), blocked 
with 5% milk in PBST and incubated with primary antibody overnight at 4 °C. Secondary 
antibody was added for 1 h at ambient temperature and blots were detected with SuperSignal 
West Pico Chemiluminescent Substrate (Pierce).  
Normal human melanocytes, and likewise melanoma cells, were seeded on glass 
coverslips and fixed with 2% formaldehyde for 30 min at ambient temperature. After washing 
with PBS, cells were treated for 5 min with 0.2% Triton-X on wet ice and blocked with 5% goat 
serum for 30 min at ambient temperature. Incubation with anti-tenascin-C diluted in 1% goat 
serum was performed for 2 h at ambient temperature. After washing extensively with PBS, 
secondary goat anti-mouse 488-Alexa Fluor antibody (Molecular Probes, Invitrogen) was added 
for 1 h. Actin fibers were stained with rhodamin phalloidin (Invitrogen) for 40 min at ambient 
temperature and nuclei were stained with DAPI. Slides were mounted and images were acquired 
with a 60X objective using an Olympus BX-40 microscope.  
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2.5.10 Immunohistochemistry in SOCs 
5µm sections of paraffin embedded specimens were cut, transferred to poly-L-lysine 
coated slides and deparaffinized 2 hours at 58°C. Slides were then dewaxed in xylene, rehydrated 
in series of desending grades of alchocol and washed with deionized water. Antigens were 
retrieved for 15 min in 1% pepsin in 10mM HCl for TNC staining or heat induced for 20min in 
citrate biffer pH6 (Dako, Carpinteria, CA) for ACN-4 staining. Endogenous peroxidase was 
blocked with 3% H2O2, and sections were then incubated in 5% goat serum to decrease 
background staining. Sections were incubated with primary antibodies for 2h in humified 
chamber in 37°C incubator, washed and incubated with biotinilated secondary goat anti-mouse 
antibody (Jackson ImmunoResearch, West Grove, PA) at 1:250 dillution. Vectastatin ABC kit 
(PK-6100) and DAB peroxidase kit (SK-4100) were both form Vector Laboratories (Burlingame, 
CA). Slides were counter stained with Meyer’s hematoxylin (Vector Laboratories), dehydrated 
and mounted with Permount solution (Fisher Scientific, Pittsburgh, PA). Images were acquired 
with a 10X objective using Olympus BX-40 microscope and SPOT imaging software (Sterling 
Heights, MI). 
2.6 SUPPORTING INFORMATION 
 
The complete list of peptides/proteins, identified in the various SOC sections and the 
melanoma and skin tissue samples are listed in Appendix A (Global protein and peptide results 
for the skin organ construct FFPE tissue samples (Tabs 1 and 2 respectively) and biopsy tissue 
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sample (Tabs 3 and 4 respectively) analyses. Xcorr, Sequest cross correlation score; DeltaCn, 
Sequest delta correlation score.).  
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3.1 ABSTRACT 
Tenascin C (TNC), overexpressed in invasive growths, has been implicated in 
progression of melanoma but the source and function of this molecule are not well defined. We 
found TNC expression at the front of invading melanoma cells, and that adding TNC to matrices 
enhances individual melanoma cell migration. As TNC is a multidomain protein, we examined 
the role of the TNC EGF-like repeats (EGFL) as these activate motogenic signaling cascades. 
We overexpressed a TNC fragment containing the assembly and EGFL domains of TNC 
(TNCEGFL). TNCEGFL-expressing melanoma cells had lower speed and persistence in 2D 
migration assays due to a shift in the adhesion-contractility balance, as expression of TNCEGFL 
delayed melanoma cell attachment and spreading. The less adhesive phenotype was due, in part, 
to increased ROCK signaling concomitant with MLC2 and MYPT phosphorylation. Inhibition of 
ROCK activity, which drives transcellular contractility, restored adhesion of TNCEGFL 
expressing melanoma cells and increased their migration in 2D. In contrast to the diminished 
migration in 2D, TNCEGFL-expressing melanoma cells had higher invasive potential in 
Matrigel invasion assays, with cells expressing TNCEGFL having amoeboid morphology. Our 
findings suggest that melanoma-derived TNC EGFL play a role in melanoma invasion by 
modulating ROCK signaling and cell migration.  
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3.2 INTRODUCTION 
 
Melanoma, which continues to increase in frequency, has a very low response rate to 
current therapies, with the tumor invading through a collagen-rich dermis to disseminate to 
ectopic sites. The transition from melanoma in situ and radial growth phase (RGP) to the vertical 
growth phase (VGP) melanoma is poorly understood. The invasive aspects of tumor progression 
represent complex molecular events, which involve recognition and remodeling of extracellular 
matrix (ECM), changes in intracellular signaling and reorganization of the cytoskeleton, 
allowing for enhanced motility of tumor cells (Friedl and Gilmour, 2009; Wells, 2000). While 
there are numerous changes in both the melanoma cells and the dermis during this progression, 
one striking feature is the re-expression of Tenascin C (TNC) (Hood et al., 2010; Ilmonen et al., 
2004; Kaariainen et al., 2006). TNC is an extracellular matrix protein linked to development and 
tissue regeneration along with tumor invasion (Jones and Jones, 2000b; Midwood et al., 2011). 
TNC is barely detectable in normal skin, but present in substantial amounts in advanced 
melanoma particularly at the invasive fronts and lack of detectable TNC in primary melanoma 
lesions has been shown to correlate with a lower risk of developing metastases (Kaariainen et al., 
2006). In the tumor microenvironment, TNC is produced by both transformed tumor cells and 
stromal cells (De Wever et al., 2004; Hanamura et al., 1997; Yoshida et al., 1997) and in vitro, 
the majority of human melanoma cell lines secrete TNC (Herlyn et al., 1991). Thus, an open 
question remains of whether the TNC expressed by the melanoma cells can drive tumor cell 
invasion.  
TNC is a hexameric protein composed of 180 to 320 kDa monomers, which are disulfide 
linked at the N-termini. Each subunit contains: a globular N-terminal assembly domain, a 
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domain composed of 14.5 Epidermal Growth Factor-like (EGFL) repeats, a domain composed of 
fibronectin type III-like (FNIII) repeats, and a fibrinogen-like sequence on the C terminus 
(Aukhil et al., 1993), and each domain has a potentially distinct role (Jones and Jones, 2000b). 
Tenascin C has been shown to modulate many of the processes involved in cell migration and 
invasion (reviewed in (Orend, 2005; Orend and Chiquet-Ehrismann, 2006). The majority of 
cancer cell lines fail to attach on TNC coated surfaces (Huang et al., 2001), with some 
exceptions where TNC is adhesive (Paron et al., 2011), while endothelial cells attach and spread 
on TNC (Sriramarao et al., 1993). In addition, soluble and substratum-adsorbed TNC have 
distinct effects on cell adhesion and proliferation (Orend and Chiquet-Ehrismann, 2000). These 
seemingly discrepant findings are in part traceable to the different signaling propensities of the 
multiple domains of TNC being impacted by the presence of other matrix components and the 
potentially differential effects of signals in two- versus three-dimensions. 
We have previously reported that distinct EGFL repeats of TNC bind and signal through 
the EGF receptor in a novel manner as ultra low affinity/high avidity ligands (Iyer et al., 2007a; 
Swindle et al., 2001). The ‘staccato’ nature of the individual EGFL repeat binding to the receptor 
results in an anti-adhesive phenotype that must be balanced by the adhesive matrix proteins or 
even the fibronectin-like repeats of TNC.  In the presence of adequate pro-adhesive moieties, 
these EGFL repeats restrict signaling to the plasma membrane and preferentially activate a 
motogenic signaling cascade (Iyer et al., 2008).  As little is known about TNC matrikine role in 
melanoma we tested the role of EGFL repeats in melanoma motility and invasion. Herein we 
report that TNC promotes melanoma cell invasion and that this activity can be localized to the 
EGFL repeats.  
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3.3 RESULTS 
3.3.1 Advanced melanoma cell lines express TNC and increase migration in response to 
exogenous TNC 
In melanoma, TNC is present at high concentrations in the dermal matrix having 
increased from negligible levels in normal dermis (Hood et al., 2010; Kaariainen et al., 2006; 
Tuominen and Kallioinen, 1994). We examined TNC expression in human melanoma tissue 
microarray with the antibody specific for the EGFL repeats of Tenascin C (ab6393) and observed 
that it’s expression increases with melanoma progression (Figure 14A). To test whether 
melanoma cell derived TNC could be involved in dissemination we first examined expression 
levels in three melanoma cell lines derived from different stages. The WM35 cells derived from 
superficial spreading melanoma (RGP/VGP) expressed little if any TNC, similar to human 
melanocytes (Hood et al., 2010), while VGP WM983A cells and metastatic growth phase (MGP) 
cells derived from the same patient WM983B expressed high levels of TNC ( Figure 14B). This 
TNC was incorporated into the cell-generated matrix in the extracellular space and, of greater 
interest, the melanoma-derived TNC was being secreted asymmetrically at the front of the 
invading melanoma cells, as observed by confocal microscopy during the invasion of a Matrigel 
matrix (Figure 14C and D). In fact, we found that invasiveness of the three melanoma cell lines 
directly correlated to the TNC expression levels (R2=0.83) (Figure 14E). These data strongly 
suggest a role for TNC, derived from the melanoma itself as driving transmigration.  
As motility is a predictive aspect of tumor invasion (Kassis et al., 2001; Wells, 2000) and 
consistent with reports of TNC being motogenic (Chung et al., 1996; Iyer et al., 2008; Nishio et 
al., 2005; Paron et al., 2011; Swindle et al., 2001), melanoma cell lines expressing higher levels 
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of TNC migrated faster in live cell tracking experiments and had greater directional persistence, 
as measured by cell track straightness (Figure 14F, white bars). That the increase in cell speed 
was due to the TNC incorporated into the substratum was shown by adding TNC to the 
Collagen-I coating on tissue culture dishes; this further increased melanoma migration of all 
three cell lines tested (Figure 14F, gray bars). Additionally, there was high correlation (R2=0.99) 
between levels of TNC being expressed by melanoma cells, but not with exogenously added 
TNC, and cell track straightness. Cell track straightness is a measure of directionality of cell 
movement and is a ratio between displacement of a cell and the track length for a set period of 
time implying a directional component to the endogenously expressed TNC. These data suggest 
that both endogenously produced and exogenously presented TNC contribute to melanoma 
migration, but that the cells asymmetrically place the endogenously produced TNC to promote 
directional translocation. 
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Figure 14.  Expression of TNC in human melanoma samples and cell lines and its influence 
on melanoma cell invasion and migration.  
(A) TMA (tissue micro-array) stained with the antibody recognizing EGFL repeats of 
TNC (ab6393) (brown) and counterstained with hematoxylin. Scale bar 50µm. Shown are 
representative primary tumor samples. (B) Immunoblot and (C) immunostaining analyses show 
increased TNC protein expression and extracellular deposition in VGP and MGP phase 
melanoma cell lines compared to a cell line derived from superficially spreading melanoma. 
Scale bars are 50µm. Images are representative of at least three independent experiments. (D) 
During invasion in Matrigel, TNC is deposited at the fronts of WM983A cells. The size of the 3D 
model is: width 83µm, height 85µm, depth 63µm. (E) Melanoma cell lines expressing higher 
amounts of TNC invade to a greater extent in Matrigel invasion assays (R2=0.83). Shown is the 
mean ± SD of three experiments. (F) Melanoma cell speed (left panel) increases on surfaces 
coated with Collagen I -Tenascin C mixture compared to Collagen I alone, while cell track 
straightness (displacement divided by total track length, right panel) correlates with the levels of 
endogenous TNC expression (R2=0.99) but does not change upon exogenous addition of TNC. 
Box and whisker plots summarize average from three independent experiments, N > 50 tracks 
per treatment in repeated experiments. *p < 0.05, ** p < 0.01 (box encompasses 25-75%, with 
bars 10 (square)-90 (X)%, median is the triangle).  
3.3.2 TNCEGFL expression impairs migration of melanoma cells in 2D 
TNC is distinguished from most of the other Tenascin family members by the inclusion 
and/or extent of the EGF-like repeat region. We have reported that at least some of these EGFL 
repeats function as cryptic growth factors that preferentially promote motility (Iyer et al., 2007a; 
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Swindle et al., 2001). As multivalent concatamers of EGF-like repeats are difficult to synthesize 
and pose challenges to incorporating into matrices, we over-expressed the Tenascin C EGF-like 
repeats transcript in the WM983A cell line (WM983A-TNCEGFL), a cell line already 
expressing substantial amounts of endogenous full length TNC, but responding to additional 
exogenous TNC (Figure 14). A vertical growth phase melanoma cell line was chosen as a model 
system as an intermediate phenotype of the cell lines tested regarding motility in 2D and 3D 
assays, so that changes in both directions can be observed. The TNCEGFL monomer ran in 
PAGE analyses at the predicted size of 69kDa and, as assessed under non-reducing conditions, 
assembled in polymers with the endogenous full length TNC (Figure 15A). Staining with 
antibody that recognized the EGFL repeats (MAB2138, R&D Systems) revealed that TNCEGFL 
formed punctuated extracellular network, compared to WM983A cells transfected with an empty 
vector (WM983A-EV), which formed prominent fibrilar TNC mesh, supporting the role of TNC 
FN repeats in organization of TNC extracellular network (Ramos et al., 1998) (Figures 15B, 
lower panel and 18B). Interestingly, while WM983A-EV cells arranged themselves in a 
distributed mesh, the WM983A-TNCEGFL cells aligned to form cords (Figure 15B, upper 
panel).  
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Figure 15. Expression of TNCEGFL in WM983A cell line. 
(A) Immunoblotting of TNC under non-reducing conditions with the antibody recognizing EGFL 
repeats (R&D Systems): whole cell lysates and matrix are shown in the left and conditioned 
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melanoma media are in the right. Graphic depiction of the full length TNC and TNCEGFL 
construct is provided. (B) Immunostaining of TNC: endogenous TNC forms fibrilar mesh in the 
ECM while TNCEGFL is punctuate (lower panel 60X, arrow heads point to the TNC fibers and 
punctae, respectively), WM983A-TNCEGFL forms organized cords compared to unorganized 
WM983A-EV cell distribution (upper panel 20X). Scale bars 50µm.  
 
Of interest, and unexpectedly, WM983A-TNCEGFL cells migrated significantly slower 
in a 2D wound healing assay that measures directional collective 2D migration (Figure 16A) and 
presented individually at a significantly reduced average speed in live cell tracking experiments 
(3.9 nm/s) compared to WM983A-EV cells (4.5 nm/s) (Figure 16B). Moreover, cell track 
straightness was significantly reduced (Figure 16B right panel) in WM983A-TNCEGFL cells, 
suggesting that the loss in cell movement directionality in 2D is contributing to decrease in 
collective cell migration. The phenotype was confirmed in WM35 cell line, which expresses 
little if any endogenous TNC. Upon transient expression of either full length TNC or TNCEGFL 
average cell speed and cell track straightness significantly decreased in 2D live cell tracking 
experiments with the TNCEGFL cells migrating the slowest (Figure 17). This confirms the 
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findings with the over-expression of TNC constructs in the invasive melanoma cells.
 
Figure 16. WM983A-TNCEGFL cells present impaired 2D cell migration. 
(A) WM983A-TNCEGFL cells migrate significantly slower in wound healing assays. 
Scale bar 200µm. The graph shows mean ± SEM of three experiments each in triplicate. (B) 
Individual cell speed and track straightness of WM983A-TNCEGFL cells are significantly 
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decreased compared to WM983A-EV cells. N > 50 tracks per phenotype (box encompasses 25-
75%, with bars 10%-90%, median is the triangle). * p < 0.05, ** p < 0.01. 
 
 
 
 
Figure 17. Expression of TNCFULL or TNCEGFL impairs WM35 cell migration. 
 (A) Immunoblotting of TNC under non-reducing conditions with the antibody 
recognizing EGFL repeats (R&D Systems) and ppMLC: whole cell lysates and matrix at the end 
of live cell tracking experiment; increased ppMLC in cells transfected with TNC constructs. 
Intensities of protein bands were determined by integrating optical density over the band area 
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using Image J software, normalized to the GAPDH levels and divided by the lane 1. (B) 
Individual cell speed and track straightness of WM35 cells transfected with TNCFULL or 
TNCEGFL are significantly decreased compared to WM35-EV cells. N > 50 tracks per 
phenotype. * p < 0.05, ** p < 0.01. TNCEGFL expressing cells have more severe phenotype 
than TNCFULL. 
3.3.3 TNCEGFL expression impairs melanoma cell attachment 
Migration speed in 2D results from a balance in adhesion and contractility in a biphasic 
manner (DiMilla et al., 1991; DiMilla et al., 1993; Lauffenburger and Horwitz, 1996). Decrease 
in adhesiveness could alter the cell speed in increasing or decreasing manner, depending on the 
initial adhesiveness to substratum. Examining this aspect, we found that TNCEGFL expressing 
cells were slower to adhere to and spread on substrata (Figure 18A). In cell spreading assays, 
TNCEGFL expressing cells started spreading with a 4h lag compared to cells expressing an 
empty pcDNA3.1 vector (Figure 18A). Furthermore, attachment of WM983A cells was inversely 
correlated to the amount of TNCEGFL repeats being expressed (Figures 18A and B). While 
over-expression of the full length of TNC (TNCFULL) did not impair cell attachment, 
expression of the EGFL repeats suppressed attachment in dose dependent manner. This 
phenotype was intrinsic as the difference in cell spreading and migration between WM983A-
TNCEGFL and WM983A-EV persisted on plastic culture dishes or Fibronectin-1 coated 
surfaces (Figure 19). The difference in adhesiveness was not likely due to altered attachment 
proteins as the integrin profile of the TNCEGFL-expressing cell line remained the same as the 
one transfected with an empty vector, as determined by PCR Array (SABiosciences, PAHS-
013A) (Table 3) nor was this an artifact of cell death as 48 hours post plating there were equal 
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cell numbers (Figure 18B). The reduced adhesion and spreading were due to an anti-adhesive 
phenotype of the EGFL repeats, as quantified in inverted centrifugation assays. Adherent 
WM983A-TNCEGFL cells detached to a greater extent when subjected to centrifugal force than 
WM983A-EV cells (Figure 18C).  
Table 3. Integrin profiles of WM983A-EV and WM983A-TNCEGFL cell lines determined by 
PCR array 
 WM983A-TNCEGFL WM983A-EV  
gene symbol Ct Ct fold change 
ITGA1 25.60 26.23 1.34 
ITGA2 28.35 29.09 1.45 
ITGA3 25.85 25.87 0.88 
ITGA4 21.79 22.03 1.03 
ITGA5 25.92 25.40 0.61 
ITGA6 20.59 20.59 0.87 
ITGA7 30.17 30.58 1.16 
ITGA8 35.00 35.00 0.87 
ITGAL 34.60 34.81 1.01 
ITGAM 32.18 35.00 6.14 
ITGAV 22.20 21.86 0.67 
ITGB1 20.05 20.14 0.93 
ITGB2 33.03 35.00 3.41 
ITGB3 25.83 26.14 1.08 
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ITGB4 34.74 34.18 0.59 
ITGB5 25.15 25.95 1.51 
     
HPRT1 22.04 21.83  
RPL13A 19.21 18.89  
GAPDH 17.24 16.99  
ACTB 14.33 15.34  
 
 * The grey shaded genes’ average threshold cycle is relatively high (> 30), meaning that 
its relative expression level is quite low and thus quantitation is difficult, in both control and test 
samples, and thus, fold changes while in two seemingly significant, are likely biologically 
irrelevant. All other changes for mRNA that are present at readily measurable levels are not 
statistically significant. 
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Figure 18. WM983A-TNCEGFL cells present impaired cell spreading and 
attachment that is TNCEGFL dose dependant.  
> 
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(A) Cells were imaged at the indicated times after seeding by phase contrast microscopy 
and scored for the percentage of spread cells (upper panel). Lower panel shows the difference in 
cell spreading at 6h. Shown are representative of three experiments. Scale bar 100µm. (B) 
Immunostaining of TNC in two clones of WM983A-TNCEGFL (C1 and C3) and the full length 
TNC (TNCFULL) construct. (C) WM983A-TNCEGFL detached to a greater extent in inverted 
centrifugation assays. Shown is an average ± SEM of three experiments, each in triplicate. *  p < 
0.05. 
 
 
Figure 19. TNCEGFL expressing cells have anti adhesive phenotype that persists on 
Fibronectin coated surfaces and have unchanged proliferation rates compared to 
WM983A-EV cells. 
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(A) Quantification of cell attachment assay (left panel) and wound healing assay (right 
panel) on 2µg/cm2 fibronectin coated surface. (B) Number of WM983A-EV and WM983A-
TNCEGFL cells 48h post plating determined with trypan blue dye exclusion. 
3.3.4 Expression of TNCEGFL activates ROCK signaling 
The critical aspect of both cell migration and attachment/spreading is the ratio of 
adhesion to transcellular contractility (Lauffenburger and Horwitz, 1996). As integrin profiles 
were similar and the phenotype persisted across different substrata, we focused on contractility 
that creates tension within the cell and determines the round cell shape (reviewed in (Sanz-
Moreno and Marshall, 2010)), mainly the Rho-associated kinase (ROCK) and myosin light chain 
2 (MLC2). ROCK inhibitor Y27632 dramatically improved adhesion and spreading of 
WM983A-TNCEGFL cells when added at the time of plating (Figure 20A). 2D migration of 
WM983A-TNCEGFL cells was slightly but statistically significantly increased when 5µM 
Y27632 was added at the time of introducing “the wound”, compared to the WM983A-EV 
(Figure 20B). This is in accordance with findings that inhibition of ROCK in the absence of 
three-dimensional environment enhances cell movement (Sahai and Marshall, 2003) as it allows 
generation of protrusions and adhesion of the leading edge.  
Activated ROCK affects the state of MLC2 phosphorylation by direct phosphorylation of 
MLC2 and by phosphorylation and inhibition of MLC phosphatase (Amano et al., 2000). 
Phosphorylation of MLC2 on Ser-19 is only partially dependent on ROCK whereas 
diphosphorylation on both Thr-18 and Ser-19 and myosin phosphatase phosphorylation (which is 
inhibitory to this contractility antagonist) on Thr-853 are ROCK dependent (Ren et al., 2004). It 
has been shown that upon cell detachment Rho-ROCK signal transduction is disrupted (Ren et 
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al., 2004).  Therefore, we examined the phosphorylation status of these molecules in trypsinized 
(detached) and replated WM983A-EV and WM983A-TNCEGFL cells during the time course of 
8 hours (Figure 20C). We observed that after detachment phosphorylation levels drop and during 
the course of attachment WM983A-EV cells gradually increase diphosphorylation of MLC2 
(ppMLC2) while TNCEGFL expressing cells have constant higher levels of ppMLC2. 
Monophosphorylation on Ser-19, as expected, did not differ in WM983A-TNCEGFL cells 
compared to WM983A-EV. Increased diphosphorylation of MLC2 may induce premature 
contraction and decreased spreading, the phenotype that we observe in TNCEGFL expressing 
cells. Additionally, in TNCEGFL expressing cells phosphorylation of Thr-853 MYPT, myosin-
binding subunit of myosin phosphatase, that inhibits its phosphatase activity, was increased 
compared to WM983A-EV. Furthermore, transient expression of TNCFULL or TNCEGFL in 
WM35 cells increased basal levels of ppMLC (Figure 17A) As adhesion provides physical 
support for contraction and effective migration on rigid substrates, our results imply that overly 
activated ROCK and its effectors in TNCEGFL expressing cells lead to impaired cell attachment 
and movement in 2D.  
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Figure 20. Expression of TNCEGFL activates ROCK signaling.  
(A) Effects of ROCK inhibitor Y27632 on WM983A cell spreading (shown at 4h post 
plating (left panel) and quantification (right panel)) and migration (B). Shown is mean ± SEM of 
three experiments each in triplicate, * p > 0.05. Scale bars 50µm. (C) Phosphorylation of the 
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downstream ROCK effectors MLC2 and MYPT in WM983A-TNCEGFL cells during the course 
of attachment compared to WM983A-EV. Intensities of protein bands determined by integrating 
optical density over the band area using Image J software, normalized to the GAPDH levels 
showed increases between 1.5 to 2.0 fold across all three repeats for WM983A-TNCEGFL 
ppMLC and pMYPT levels compared to WM983A-EV across time points.  
 
3.3.5 TNCEGFL expressing melanoma cells have increased invasion potential 
The foregoing presents a cell that is less attached to the substrata, and likely exhibits 
greater shape plasticity, and thus may preferentially move through a 3D matrix (Friedl et al., 
1998; Wolf et al., 2003). To address the question of the role of TNCEGFL in 3D migration and 
invasion we performed Matrigel invasion experiments. WM983A-TNCEGFL cells had rounded 
morphology in Matrigel, as observed by confocal microscopy, and the phenotype could be 
reverted to the elongated mesenchymal type in the presence the ROCK inhibitor (Figure 21A). In 
addition, WM983A-TNCEGFL cells invaded to a greater extent than WM983A-EV cells (Figure 
21B). Confocal imaging of individual invading cells in 3D revealed that WM983A-TNCEGFL 
cells had rounded blebbing morphology with high diphosphorylated MLC present in the invading 
blebs, compared to WM983A-EV cells which had a mesenchymal morphology with filamentous 
protrusions (Figure 21C). Increased invasion potential was not due to increased gelatinase 
activity as the activities of MMP2 and MMP9 did not change (Figure 22).  Our findings are in 
line with the notion that round melanoma cells are able to squeeze through gaps in ECM more 
readily (Gaggioli and Sahai, 2007) as a result of strengthening of the Rho/ROCK signaling 
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pathway as one of the mechanisms leading to mesenchymal to amoeboid migration transition 
(reviewed in (Friedl, 2004)).   
Finally, we tested the ability of WM983A-EV and WM983A-TNCEGFL cells to invade 
into the collagen-rich dermis of all-human skin organ cultures, a model that better captures 
melanoma invasion in the human skin. While WM983A-EV cells disrupted formation of 
stratified epidermis, they did not invade into dermis in the 20-day period. On the contrary, 
WM983A-TNCEGFL cells were able to penetrate in the dermis compartment of skin organ 
cultures (Figure 21D). 
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Figure 21. TNCEGFL expressing cells have rounded morphology in 3D and present 
higher invasion potential.  
(A) Morphology of WM983A-EV and WM983A-TNCEGFL cells seeded in Matrigel in the 
absence or presence of Y27632 inhibitor. Scale bars 100µm. (B) Extent of invasion into Matrigel 
after 48h, in the absence or presence of Y27632 inhibitor, results are shown relative to the 
WM983A-EV invasion, average ± SD n=3, * p < 0.05. (C) Confocal stacks of individual 
WM983A-EV and WM983A-TNCEGFL invading cells in 3D Matrigel, immunostained for 
diphosphorylated MLC (Cell Signaling). Arrowheads point to actin protrusions and blebs, 
respectively. The left hand part of each image is the Z stack in the transverse plane through the 
cell, whereas the right hand part is the coronal section with the depth to the left. Scale bars 
10µm. (D) Representative images of H&E stained skin organ cultures seeded without or with 
WM983A-EV and WM983A-TNCEGFL melanoma cells after 20 days of culture. Arrow points to 
invading WM983A-TNCEGFL cells. Scale bar 100µm. E-epidermis, D-dermis, M-melanoma. 
These results are representative of three independent experiments.  
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Figure 22. TNCEGFL expressing cells have unchanged MMP2 activity compared to 
WM983A-EV cells.  
Gelatin zymogram of WM983A-EV and WM983A-TNCEGFL conditioned medium or cell 
lysates.   
3.4 DISCUSSION 
The most important step in progression from melanoma in situ to advanced metastatic 
disease is acquiring invasive ability. Advanced melanomas produce substantial amounts of TNC 
that are thought to form fibrillar channels allowing invasion (Kaariainen et al., 2006). Down-
regulating TNC in melanoma cells leads to impaired lung colonization and metastasis formation 
(Fukunaga-Kalabis et al., 2010); this was also observed in TNC-deficient breast cancer cells in 
which TNC maintains the metastatic niche (Oskarsson et al., 2011). Therefore, increased levels 
of TNC secreted by melanoma cells may not only promote tumor invasion but also contribute to 
metastatic seeding. Despite the phenomenological descriptions, the actual cellular mechanisms 
by which TNC contributes to invasiveness of melanoma are not defined. Herein, we show that 
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one aspect driven by TNC is the enhanced migration through matrices signaled by the EGFL of 
this matrix molecule. 
In this report we show that advanced melanoma cell lines themselves express large 
amounts of TNC that is incorporated into the extracellular matrix, and further respond to 
exogenous TNC by increasing migration speed. We observe that asymmetrical placement of 
TNC at the cells’ front may promote directional translocation during melanoma cell invasion. As 
TNC is susceptible to proteolytic degradation by MMPs (Imai et al., 1994; Siri et al., 1995) and 
EGFL repeats can be released or ‘uncovered’ by this cleavage (Wallner et al., 2004), we focused 
in particular on the possible impact of TNCEGFL repeats on melanoma cell migration and 
invasion. We show that overexpressing TNCEGFL impairs TNC extracellular network 
organization and confers intrinsic anti-adhesive phenotype to melanoma cells, which is EGFL-
dose dependent. We find that TNCEGFL-expressing cells migrate slower in 2D motility assays 
but move and have increased invasion potential in 3D systems. Invading TNCEGFL expressing 
cells have rounded cell morphology, consistent with reports that melanoma cells can shift to a 
less adhesive amoeboid mode of cell movement (Sahai and Marshall, 2003). This dichotomy of 
migration potential in 2D and 3D matrices has been noted previously with a shift in the adhesion-
contractility towards a lesser overall value promoting speed through 3D matrices while 
diminishing the locomotion on 2D surfaces (Zaman et al., 2006). The mechanism of this shape 
plasticity in presence of TNCEGFL points to ROCK signaling that has been shown to allow 
melanoma switching between mesenchymal and amoeboidal types of cell movement (Sahai and 
Marshall, 2003; Sanz-Moreno and Marshall, 2009). This is consistent with signaling of the 
EGFL repeats via the EGFR. However, we could not definitively demonstrate such a pathway as 
EGFL repeats being at ultra-low affinity (Swindle et al., 2001) and melanoma cells expressing 
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low levels of steady state EGFR; further, the melanoma cells did not survive in the face of EGFR 
inhibition (data not shown). Nevertheless, Proximity Ligation Assays (PLA) (Soderberg et al., 
2006) implicate a close physical association (<40nm) of TNC and EGFR in these melanoma cells 
(Figure 23). Still in the absence of definitive evidence, it is possible that the EGFL repeats signal 
via other surface receptors.  
 
Figure 23. Proximity ligation assay for physical association of EGFR and TNC.  
PLA assay was performed with primary anti EGFR antibody (Cell signaling) and anti 
TNC antibody that recognizes EGFL repeats (ab6393, Abcam). Close physical association of the 
two proteins is visualized as a red fluorescent signal. (A) Representative maximum intensity 
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projections from 20 planes 1 µm apart. PLA signal is red, nuclei stained with DAPI. (B) Average 
integrated density of the red signal per cell in each plane was calculated with Image J software 
Particle Analyzer. The distance of 20 represents the surface of the coverslip. 
 
It has been described that amoeboid-like melanoma cells that have high ROCK activity 
are found at the invasive fronts of melanomas, while mesenchymal elongated cells comprise the 
body of the tumors (Sanz-Moreno et al., 2011). We find that TNCEGFL-expressing cells have 
increased ROCK signaling, as observed by increased phosphorylation of its targets: 
biphosphorylation of MLC2, that increases transcellular contractility, and phosphorylation of 
MYPT, that negates the inhibition of actin cytoskeleton contraction. This is validated by the loss 
of the anti-adhesive phenotype and rounded morphology in presence of the ROCK inhibitor 
Y27632 on both rigid 2D substrates and in 3D Matrigel. Furthermore, in the blebs of TNCEGFL 
expressing cells invading the 3D matrices, diphosphorylated MLC2 co-localizes with the actin 
cytoskeleton; this is characteristic of contractile amoeboid type of movement (reviewed in 
(Lammermann and Sixt, 2009)). Finally, we show that TNCEGFL expressing cells are more 
efficient in invading into a human skin organ culture, a setting that better resembles the first 
steps of actual melanoma invasion in patients.  
Supporting our signaling model, it has been shown that recombinant TNC construct 
Ten70 which does not contain EGFL repeats, suppresses Rho A activation while maintaining the 
level of active Cdc42 thus preventing stress fiber formation (Wenk et al., 2000). Cells seeded on 
Ten70 form prominent filopodia, and that exact feature is lost in TNCEGFL-expressing 
melanoma cells. By overexpressing EGFL repeats, the balance of endogenous signaling of TNC 
is shifted and activation of ROCK enables amoeboid morphology. Our results are in concordance 
 84 
with observation that distinct modes of cell motility have different requirements for ROCK 
activity (Sahai and Marshall, 2003), as TNCEGFL expressing cells perform better in 3D 
migration assays and have impaired migration in 2D assays compared to melanoma cells 
transfected with an empty vector. It is interesting to speculate that TNC, highly expressed at the 
invasion fronts of melanoma (Kaariainen et al., 2006) and at the front of invading melanoma 
cells promotes activation of ROCK and amoeboid cell morphology observed at the fronts of 
invasion in melanoma tumors (Sanz-Moreno et al., 2011). 
Taken together, our data demonstrate that over expression of TNCEGFL repeats alters 
both adhesive and migratory states of melanoma cells and the composition of the extracellular 
matrix making it more permissive for melanoma cell invasion. The rounded morphology and 
enhanced blebbing of the amoeboid form of motility allows for cells to more easily penetrate 
smaller sized pores in matrices and thus are less dependent on proteolytic ‘opening’ of channels 
in a collagen-rich matrix such as the dermis (Friedl, 2004). Our findings also reinforce the notion 
that cells utilize different signaling cascades to effect migration dependent on the 2D versus 3D 
matrix context.  
3.5 MATERIALS AND METHODS 
3.5.1 Cell culture 
Melanoma cell line WM35, obtained from Coriell Institute for Medical Research 
(Camden, NJ), was maintained in MCDB153: L15 4:1 medium mixture with addition of 5% 
FBS, 5µg/ml insulin and 2mM CaCl2. WM983A and WM983B were obtained from Wistar 
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Institute (Philadelphia, PA) and cultured in DMEM: L15 3:1 mixture with addition of 10% FBS 
(Herlyn et al., 1991). Human epidermal keratinocytes were obtained from Invitrogen and 
cultured on collagen-coated dishes in Epilife medium with growth supplements (Invitrogen, 
Grand Island, NY). Human neonatal fibroblasts were cultured in DMEM with 10% FBS. Primary 
cells were used in skin organ cultures under 6th passage. 
3.5.2 Generation of TNCEGFL and TNCFULLL constructs and TNCEGFL expressing 
melanoma cell lines 
Full length TNC construct (X78565) was obtained form Dr. Harold Erickson (Duke 
University, Durham, NC)(Aukhil et al., 1993). The first half of the TNC sequence was amplified 
with introduced NotI and EcoRV cutting sites, of total length of 2355 bases, and cloned into 
pcDNA3.1(-) vector (Invitrogen). The primers for amplification were 5’-ATA CTC AAG CGG 
CCG CAT GGG GGC CAT GAC TCA-3’ and 5’-CGG ATA TCT CAT ACT CTT GCC CAG 
GA-3’. Subsequently, TAA stop codon was introduced instead of TCA codon at the end of 14th 
EGFL repeat with Quick Change II Site Directed Mutagenesis Kit (Stratagene) and primers 5’-
GGG AGG AGA CAC CTCTTA GCA GTC TTC TCC G-3’ and 5’-CGG AGA AGA CTG 
CTA AGA GGT GTC TCC TCC C-3’. WM983A cells were transfected with TNCEGFL using 
Lipofectamine (Invitrogen) and G418 resistant clones were selected. Clone expressing the 
highest amount of TNCEGFL (C1) was selected for further analysis and clone with lower level 
of TNCEGFL expression (C3) for comparison in some assays. As a control, a monoclonal 
WM983A isolate expressing empty pcDNA3.1(-) vector was established. For the TNCFULL 
construct the full length TNC was cloned into the same vector and G418 resistant clones were 
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selected. The same vectors EV, TNCEGFL and TNCFULL were used for transient transfection 
in WM35 cell line. 
3.5.3 TNC TMA immunohistochemistry 
Melanoma tissue microarrays ME1004 and ME242 were purchased from Biomax 
(Rockville, MD) and stained with anti-TNC antibody that recognizes the EGFL repeats (ab6393, 
Abcam, Cambridge, MA) as previously described (Hood et al., 2010). Images were acquired 
with an Olympus 40X 0.75 NA objective on Olympus BX-40 microscope.    
3.5.4 Immunoblotting and immunostaining 
Immunoblotting and immunostaining were performed as previously described (Hood et 
al., 2010). Antibodies used were: anti-TNC recognizing FN repeats (MAB33581, R&D 
Systems), anti-TNC recognizing EGFL repeats (MAB2138, R&D Systems), anti-pMLC2 Ser-19, 
anti-pMLC2 Thr-18/Ser-19, anti pMYPT Thr-853 (#3675, #3674 and #4563, respectively, Cell 
Signaling Technology) and anti-GAPDH (G9545, Sigma-Aldrich). All secondary antibodies 
were from Sigma-Aldrich or Molecular Probes, Invitrogen. Actin fibers were stained with 488- 
or 568-Alexa Fluor phalloidin (Invitrogen) and nuclei with DAPI. Images were acquired with an 
Olympus 60X 1.25 NA or Olympus 20x 0.4 NA objective on Olympus BX-40 microscope.    
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3.5.5 Cell spreading and inverted centrifugation assays 
For spreading assays cells were trypsinized and re-plated on plastic culture dishes in 
regular medium or in the presence of 5µM Y27632 (Calbiochem). After 2, 4, 6 and 8 hours 
images were acquired using Olympus IX70 microscope with a 10X 0.3 NA objective, cells were 
counted (n=100 per treatment) and percentage of spread cells was determined. Completely round 
phase-bright cells were counted as non-spread and those that lacked round shape and had 
membrane protrusions were counted as spread. Data was collected from three independent 
experiments. 
Inverted centrifugation assay was performed as described (Shao et al., 2010). In this 
assay, after 2, 4, 6 and 8 hours, we compared stationary plates washed with PBS against plates 
spun inverted at 1000 rpm (150g). This was used to calculate the % of attached cells compared to 
not centrifuged plate controls.  
3.5.6 2D migration assays and cell tracking 
For wound healing assay cells were seeded in regular medium and let attach 12h and then 
quesced in 0.5% FBS medium for 24h. The cross wound was introduced with a yellow pipette 
tip, and the cross was used as a reference of position for taking images. If used, 5µM Y27632 
(Calbiochem) was added at the time of introducing the wound. Images were taken at 0 and 22h 
post scratching using Olympus IX70 microscope with a 4X 0.13 NA objective. Area of the 
wound was calculated using ImageJ software and results were expressed as % of the area closed 
within 22h.  
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For imaging of single cell movement of WM35, WM983A and WM983B cells, plates 
were coated with 2µg/cm2 of rat tail Collagen I (BD Biosciences, Bedford, MA) or 2µg/cm2 of 
Collagen I and 2µg/cm2 of human Tenascin C (Millipore, Temecula, CA) in PBS for 2 hours at 
ambient temperature and then blocked for 30 minutes with 0.1% BSA in PBS. 2x104 cells per 
well were seeded and let attach for 12 hours. Cells were labeled with Cell Tracker red CMPTX 
(Invitrogen, Carlsbad, CA) and after 6h in 0.5% FBS medium imaged for 8 hours every 10 
minutes in TRITC and phase channels with Nikon 10X 0.5 NA objective on Nikon Ti-E inverted 
microscope with CO2 stage incubator (Okolabs, Quarto, Italy). Cell migration speed and track 
length and displacement were analyzed with Imaris software (Bitplane, Zurich, Switzerland) 
based on tracking of movement of fluorescence as autoregressive motion. Experiment was 
repeated two times and total of more than 50 tracks per treatment were analyzed. For tracking of 
WM35 cell movement upon expression of TNC constructs, cells were transfected with EV, 
TNCFULL or TNCEGFL, and 24h later imaged for 8h every 10 minutes. For tracking of 
WM983A-EV and WM983A-TNCEGFL cell movement, cells were seeded on glass-bottom 
dishes (MatTek Corporation, Ashland, MA) an let grow for 72 h before imaging to allow 
deposition of the matrix and then imaged and analyzed as described above. 
3.5.7 3D invasion assay 
Matrigel invasion assay was performed in BD BioCoat Matrigel Invasion Chamber per 
manufacturer instructions (354480, BD Biosciences, Bedford, MA). Cells were let to invade for 
48h or 72h as specified in the legends. The invaded cells at the bottom side of membrane were 
stained with DAPI and five random 10x fields were counted, with each condition in triplicate. 
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Experiments were repeated three times and average number of invaded cells was expressed as 
number of invaded cell per 10x field or relative to WM983A-EV.   
3.5.8 Confocal imaging of Matrigel invading cells 
Cells were seeded as for Matrigel invasion assay and let invade 48h. Matrigels were 
stained as described with modifications (Hooper et al., 2006). Briefly, Matrigel inserts were 
washed with PBS, fixed 30 minutes in 4% formaldehyde 0.25% glutaraldehyde in PBS, treated 
with 0.2% Triton X for 30 min on ice, and stained with 0.2µg/ml 568-Alexa-Fluor phalloidin 
(Molecular Probes, Invitrogen) and 2µg/ml DAPI (Sigma) in dark for 3h. After washing with 
PBS samples were incubated with anti-TNC or anti-ppMLC antibody for 12h at 4°C and another 
2h at ambient temperature with anti-rat 488-Alexa Fluor secondary antibody (Invitrogen). 
Membranes were cut out with a razor blade and mounted on glass slides in PBS. Images were 
taken on Nikon Sweptfield Confocal Microscope (TSI inverted) using 10X and 60X 1.4 NA 
objectives. 3D volume representations of Z-stacks were made using Nikon Elements software. 
3.5.9 Skin organ cultures and H&E staining 
Skin organ cultures were established as previously described (Simpson et al., 2010) with 
modifications. Briefly, 5x105 primary human fibroblasts were seeded in collagen gels, and after 5 
days in submerged culture 1x106 normal human keratinocytes were seeded on top. The next day 
1x105 WM983A-EV or WM983A-TNCEGFL cells were seeded in the center of the plug within 
the cloning rings, let attach for 8h and then the cloning rings were removed. After 3 days, the 
cultures were lifted to air liquid interface to allow epidermis maturation and medium was 
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replenished every other day for total of 20 days of culture. The samples were fixed and paraffin 
embedded and H&E stained as previously described (Hood et al., 2010). Experiment was 
repeated two times with similar results. 
3.5.10 Gelatin zymography 
Gelatinase activities of MMP2 and MMP9 in WM983A-EV and WM983A-TNCEGFL 
conditioned medium and lysates were assessed according to prior protocols (Toth and Fridman, 
2001). 
3.5.11 PCR array 
RT2 Profiler PCR Array of Human Extracellular Matrix and Adhesion Molecules (PAHS-
013A, SABiosciences, Frederick, MD) was performed per manufacturer instructions in 96 well 
format with 1µg of total RNA. Experiment was repeated two times and data was analyzed with 
SABiosciences PCR Array analysis web-based Utility 
(http://sabiosciences.com/pcrarraydataanalysis.php). 
3.5.12 Proximity ligation assay (PLA) 
WM983A-EV and WM983A-TNCEGFL cells were grown on glass cover slips, fixed 
with 4% formaldehyde, treated with 0.2% Triton-X, blocked with 5% goat serum and incubated 
with primary rabbit anti-EGFR (#2232, Cell Signaling Technology) and mouse anti-TNC 
(ab6393, Abcam) that recognizes EGFL overnight at 4°C. PLA was performed according to the 
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manufacturer’s instructions (Duolink II Red Starter kit, Olink Bioscience, Uppsala Sweden). 
Briefly, rabbit and mouse specific oligonucleotide conjugated secondary antibodies (PLA 
probes) bind to the primary antibodies. Next, probes are annealed if they are in close proximity 
(<4 0nm) and in the presence of fluorescently labeled onligonucleotides allow rolling circle 
amplification. The signal from the close physical association between the proteins of interest is 
visualized as red dots. Nuclei were labeled with DAPI and images were taken on Nikon 
Sweptfield Confocal Microscope (TSI inverted) using 40 1.2 NA objective. 20 Z plane images 
were taken every 1µm and the intensity and number of red signals were analyzed with Image J 
Particle Analyzer for at least 20 cells in each treatment, and expressed as average integrated 
density per cell. Experiment was repeated two times. Controls with single anti EGFR and anti 
TNC antibodies were performed and they gave low or no signal. 
3.5.13 Statistical testing 
All statistics of quantification in this study, including spreading assay, wound healing 
assay, Matrigel invasion assay, RT-PCR and live cell tracking experiments were performed by 
two- tailed Student's t test with a P < 0.05 being required to be considered significant and shown 
as mean ± SD or SEM (if each experiment was performed in triplicate). 
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4.1 ABSTRACT 
 
Melanoma is the most aggressive type of skin cancer with increasing incidence rates 
whose progression is characterized by drastic changes in the composition of the extracellular 
matrix (ECM).  Tenascin C in the melanoma matrix is highly up regulated and there is 
significant decrease in levels of the small leucine-rich proteoglycan Decorin compared to normal 
skin. Interestingly, both Tenascin C (TNC) and Decorin (DCN) have been shown to signal 
through the Epidermal Growth Factor receptor, with opposite outcomes on cell proliferation, 
survival and migration. We therefore examined expression of these two ECM proteins and found 
that they have opposite and almost mutually exclusive patterns of expression in benign nevi and 
primary melanoma samples. Therefore, we asked whether DCN could counteract the effects of 
increased TNC expression during melanoma invasion. DCN was able to reverse the influence of 
TNC on cytoskeletal organization and to block TNC induced increased invasion in collagen gels. 
Ultimately, in skin organ culture models DCN was able to ameliorate melanoma invasion even in 
the presence of TNC. These findings imply a role for Decorin as a preventive ECM moiety in 
melanoma invasion that could potentially be used for developing treatments. 
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4.2 INTRODUCTION 
In order to develop efficient cancer therapies it is important to identify the mechanisms 
by which tumor cells invade into surrounding tissues. Melanoma, the most aggressive cancer of 
the skin with high resistance to therapy and ability to metastasize to multiple organs, is a good 
model for studying tumor invasion partly due to its step-wise progression. Melanoma arises from 
transformed melanocytes, pigmented cells of neuroectodermal origin that normally reside at the 
basal layers of the epidermis. The majority of melanomas have a linear progression: from benign 
melanocytic nevi to the radial growth phase (RGP) melanoma that divides and spreads within 
epidermis, to vertical growth phase (VGP) during which melanoma cells invade through the 
basement membrane into dermis, reaching the final step-metastatic growth phase (MGP) that 
metastasizes to lymph nodes, lungs, liver, bones and brain (Clark et al., 1984). While melanoma 
in situ has a high cure rate by surgical resection, invasive melanoma that has penetrated dermis 
has very poor prognosis and the depth of invasion in primary tumors highly correlates with 
patient survival (Wanebo et al., 1975). It is therefore of utmost importance to elucidate changes 
that precede and/or induce melanoma invasion from the epidermis into the dermis. 
In addition to the changes in cell to cell adhesion, remodeling of the extracellular matrix 
(ECM) plays a critical role in tumor invasion as ECM proteins provide both mechanical and 
chemical signals to the tumor cells. In recent years, deciphering the regulation of tumor growth, 
invasion and metastasis by the extracellular matrix components has shed a new light on the 
sequence of events in cancer progression (Herlyn, 2009; Malanchi et al., 2012; Oskarsson and 
Massague, 2012). In melanoma, the production of ECM proteins is significantly altered 
compared to normal skin: components characteristic of an immature and healing dermis, such as 
Tenascin C, Fibronectin, certain laminins and SPARC are upregulated (Ilmonen et al., 2004; 
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Ledda et al., 1997; Natali et al., 1995; Pyke et al., 1994) while components characteristic of a 
mature matrix such as Decorin, Lumican and certain collagens are down-regulated (Hood et al., 
2010). Therefore, we asked the question whether the changes in ECM could drive melanoma 
invasion and dissemination.  
Both melanoma cells and stromal fibroblasts secrete Tenascin C (TNC) (Herlyn et al., 
1991) which has been shown to promote tumor invasion (Galoian et al., 2007; Grahovac et al., 
2012; Hancox et al., 2009; Sarkar et al., 2006). On the other hand, Decorin (DCN) is expressed 
in normal human dermis by quiescent fibroblasts (Honardoust et al., 2012; Mauviel et al., 1995), 
and can be present in melanoma tumor stroma at low levels, but is absent in melanoma cells 
themselves (Brezillon et al., 2007). Contrary to TNC, DCN has been shown to have an inhibitory 
role in cancer progression (Neill et al., 2012). Both TNC and DCN have been shown to bind the 
Epidermal Growth Factor Receptor (EGFR) (Iozzo et al., 1999b; Iyer et al., 2007a), DCN with 
the affinity of around 70nM (Santra et al., 2000; Santra et al., 2002) and TNC with lower affinity 
in the micromolar range but with high avidity due to its hexameric structure and tethering within 
the ECM (Swindle et al., 2001). DCN and TNC have different effects on EGFR signaling: DCN 
causes down-regulation of the receptor and attenuation of downstream EGFR signaling cascades 
(Zhu et al., 2005), while TNC causes sustained membrane-restricted signaling which promotes 
pro-migratory EGFR cascade (Iyer et al., 2008). Having this in mind, we explored whether DCN 
can counteract TNC promoting effects on melanoma invasion.  
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4.3 RESULTS 
4.3.1 Tenascin C and Decorin have opposite patterns of expression in melanoma tissue 
and benign nevi 
 We have previously reported comparative proteomic analysis of melanoma and the 
adjacent uninvolved skin of the same patient in which the expression of TNC was highly up-
regulated and expression of small leucine rich proteoglycans DCN and Lumican was decreased 
in melanoma samples (Hood et al., 2010). To investigate this further, we examined the 
expression of TNC and DCN in melanoma tissue array and observed that the expression of these 
two proteins is inversed in benign nevi and primary melanoma (Figure 24). Namely, TNC was 
absent in benign nevi, while the dermis was rich in DCN; on the other hand, in primary 
melanoma samples TNC was detectable throughout the samples with decreased or non-
detectable levels of DCN. Furthermore, the expression of these two proteins seemed to be almost 
mutually exclusive, as regions of the same samples rich with TNC were devoid of DCN, and vice 
versa (arrowheads, Figure 24).  
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Figure 24. Expression of TNC and DCN in benign nevi and primary melanoma. 
Representative images from the melanoma TMA stained for TNC and DCN (brick red). 
Upper panel shows benign nevi samples, and lower panel shows primary melanoma samples. 
Arrowheads point to the regions with inversed TNC and DCN expression in the same sample. 
Magnification 10X. Brown-black stain in the third and fourth lower panel samples is the 
endogenous melanin. 
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4.3.2 Tenascin C and Decorin have opposite effects on melanoma cell cytoskeleton 
 Both TNC and DCN have been reported to influence cytoskeletal organization by the 
modulation of small GTPases RhoA and Rac (De Wever et al., 2004; Tufvesson and Westergren-
Thorsson, 2003), thus affecting cell migration. This implies that the presence or absence of TNC 
and/or DCN in the melanoma ECM would modulate cell migration and invasion. We first 
examined the effects of TNC and DCN on the melanoma cell cytoskeletal organization. We 
chose two metastatic melanoma lines with different cellular morphologies (Figure 25A): 
WM983B have a more mesenchymal morphology with filopodia protrusions, while WM1158 
cells have a more spread morphology with membrane ruffling. Both cell types were seeded on 
collagen-coated surfaces (COL) with the addition of 2µg/cm2 TNC (COLTNC) or 2µg/cm2 DCN 
(COLDCN) or both (COLDCNTNC) and 24 hours post seeding cytoskeletal changes were 
detected by phalloidin staining (Figure 25B). Both cell lines seeded on COLTNC substratum had 
less spread, stretched morphology, while the cells seeded on COLDCN were spread with 
prominent stress fibers compared to cells seeded on collagen alone (Figure 25B). The addition of 
both DCN and TNC proteins counteracted the effects of one another, with cell shape resembling 
the one seen on collagen-coated surface alone. These findings imply that DCN could counteract 
the effects of TNC on cytoskeletal rearrangement, and therefore influence invasion. 
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Figure 25. TNC and DCN have opposite effects on melanoma cell cytoskeletal 
arrangement. 
(A) Bright field images of WM983B and WM1158 cells. (B) Both cell lines respond to 
TNC and DEC by cytoskeletal rearrangement. Phalloidin 568 (gray). Scale bar 50µm.  
4.3.3 Decorin can counteract Tenascin C-promoted melanoma invasion  
To test the effects of TNC and DCN on melanoma invasion we chose to examine more 
aggressive WM1158 cells, given that they presented higher migration speed in cell tracking 
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experiments and higher invasion potential in both Matrigel and collagen invasion assays (data 
not shown). WM1158 cells showed prominent invasion into 3mg/ml Collagen I gels, with both 
collective invasion and individually detaching invading cells (Figure 26A). The addition of 
4µg/ml of DCN into collagen gels decreased the collective invasion of WM1158 cells compared 
to the invasion into simple collagen gel (Figure 26C), to average 185µm depth compared to 
240µm depth of invasion in collagen alone. The addition of 4µg/ml of TNC to collagen gels 
significantly increased the extent of the WM1158 cell invasion (to average of 285µm depth). 
Moreover, the addition of TNC to collagen gels increased the number of cells that detached from 
the initial mass seeded on top of the gel (Figure 26B, detached cells (green); continuous tumor 
mass (yellow)), as quantified by Imaris software (Figure 26C). The addition of both DCN and 
TNC together dramatically decreased the collective invasion of WM1158 cells into collagen gels 
as well as the detachment of cells from the initial mass.  
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Figure 26. WM1158 cell invasion in 3D collagen gels enriched with TNC or DCN. 
(A) Confocal Z stack representation of WM1158 cells invading into collagen gels 
enriched with DCN, TNC or both. Phalloidin 488 (green), scale bar 500µm. (B) The same stacks 
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represented with Imaris software surfaces function: yellow represents continuous mass with 
detail level of 3µm, green represents cells and clusters of cells detached from the continuous 
mass 3 or more micrometers away. (C) Quantification of the depth of the melanoma cell invasion 
(D) Quantification of the volume of detached cell mass. Results are presented as average ± SD 
n=3, * p < 0.05, **p<0.01.  
 
To validate these results in more complex melanoma microenvironmental context, we 
tested the invasion of WM1158 cells in skin organ cultures (SOCs) (Figure 27). Embedding 
neonatal fibroblasts into 3mg/ml collagen gels formed the dermal compartment onto which a 
layer of normal human keratinocytes was seeded to form epidermis. WM1158 cells were seeded 
2 days after the seeding of keratinocytes to allow formation of the basement membrane between 
the epidermis and the dermis. WM1158 cells invaded into the dermal compartment of SOCs 
within 20-day time frame, both collectively and as detached cell clusters (Figure 27, upper left). 
The addition of 4µg/ml DCN into the dermal compartment prevented melanoma cells from 
invading into the dermis, and the growth was confined to the epidermis. The addition of TNC at 
the same concentration induced profound melanoma invasion into dermis, with multicellular 
streaming-like pattern. These anti and pro- invasive effects of DCN and TNC, respectively, were 
dose-dependent a 1:1 DCN: TNC ratio in the dermis induced an increased growth of the 
WM1158 mass in the epidermis, but a barely observable invasion into the dermis, while a 1:2 
DCN: TNC ratio induced an invasion into the dermis, although to the lesser extent than TNC 
alone. This implies that DCN can counteract pro-invasive TNC signals in a dose-dependent 
manner. 
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Figure 27. WM1158 cell invasion in skin organ cultures in presence of TNC and 
DCN. 
 Representative images of H&E stained skin organ cultures seeded with WM1158 and 
melanoma cells after 20 days of culture. E-epidermis, D-dermis, M-melanoma. These results are 
representative of two independent experiments.  
4.4 DISCUSSION 
 Molecular events that direct the progression from melanoma in situ to advanced 
melanoma and the microenvironmental influences on melanoma progression are two critical 
aspects the understanding of which would greatly contribute to development of new treatment 
strategies. The composition of the extracellular matrix in melanoma is significantly changed 
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compared to normal skin (Hood et al., 2010; Naba et al., 2012; Quatresooz et al., 2011) and these 
changes could drive melanoma invasion.  Here we the examined expression of two ECM 
proteins Tenascin C and Decorin in the panel of melanoma samples and found that their 
expression is opposite and almost mutually exclusive in benign nevi and primary melanoma 
samples. The presence of TNC and DCN in the ECM presented to melanoma cells had an 
opposite influence on the cytoskeletal organization and had a profound effect on melanoma cell 
invasion in 3D collagen gels. Tenascin C promoted while Decorin limited WM1158 cell 
invasion. While DCN decreased the depth of invasion in collagen gels, it did not limit WM1158 
melanoma cell detachment form the initial mass. Interestingly, DCN showed a dramatic effect on 
the cells induced to detach by TNC, and inhibited melanoma cell invasion into collagen gels 
even more in the presence of TNC then when presented alone. Ultimately, in skin organ cultures 
the presence of Decorin in the dermal equivalent was able to prevent melanoma invasion from 
the epidermis into dermis, and even in the presence of pro-invasive TNC it was able to 
ameliorate the invasion potential of melanoma cells. The mechanistic explanation of this effect, 
which was beyond this initial exploration, could be grounded in the fact that both TNC and DCN 
can bind and signal through EGFR with opposite outcomes. Select EGFL repeats of TNC have 
been shown to bind to the EGF binding pocket of EGFR (Iyer et al., 2007a), while DCN binding 
site in EGFR partially overlaps but is distinct from the EGF binding epitope (Santra et al., 2002). 
We have previously shown that EGFL repeats of TNC promote melanoma cell invasiveness by 
increasing the ROCK activity and myosin-light chain phosphorylation in migrating cells, which 
leads to a shift in mode of motility from mesenchymal to amoeboid and allows greater flexibility 
in 3D microenvironment (Grahovac et al., 2012). Decorin could simply prevent this effect by 
competing for EGFR given that it has higher affinity for the receptor (Santra et al., 2000), or 
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could signal inhibition of migration through other receptors such as c-Met, PDGFR or IGF-1R 
(Neill et al., 2012), all of which can independently contribute to melanoma invasiveness (Wu et 
al., 2012). Decorin has also been shown to inhibit melanoma migration by cellular acidification 
(Stock et al., 2011). As a natural moiety present in the skin, Decorin is an attractive candidate for 
the development of anti-melanoma therapy both as a natural kinase antagonist and as an 
enhancer of targeted gene delivery due to its collagen binding affinity (Choi et al., 2010). Further 
studies of the exact mechanistics of Decorin interference with Tenascin C are underway. 
4.5 MATERIALS AND METHODS 
4.5.1 Cell culture 
Melanoma cell lines WM983B and WM1158 were obtained from the Wistar Institute 
(Philadelphia, PA) and cultured in DMEM: L15 3:1 mixture with the addition of 10% FBS 
(Herlyn et al., 1991). Human epidermal keratinocytes were obtained from Invitrogen and 
cultured on collagen-coated dishes in Epilife medium with growth supplements (Invitrogen, 
Grand Island, NY). Human neonatal fibroblasts were cultured in DMEM with 10% FBS. Primary 
cells were used in skin organ cultures under 6th passage. 
4.5.2 Melanoma tissue microarray immunohistochemistry 
Melanoma tissue microarrays ME1004, ME1004a and ME242 were purchased from 
Biomax (Rockville, MD) and stained with anti-TNC antibody (ab6393, Abcam, Cambridge, 
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MA) or anti-DCN antibody (AF143, R&D Systems, Minneapolis, MN). Antigens were retrieved 
in 1% pepsin in 10mM HCl for TNC staining or heat-induced in citrate buffer pH6 (Dako, 
Carpinteria, CA) for DCN staining. Endogenous peroxidase was blocked with 3% H2O2, and 
sections were incubated in 5% goat or rabbit serum to decrease background staining. Sections 
were incubated with primary antibodies for 2h in a humified chamber at ambient temperature, 
washed and incubated with biotinilated secondary goat anti-mouse antibody or rabbit anti-goat 
antibody  (Jackson ImmunoResearch, West Grove, PA). Vectastatin ABC kit (PK-6100), 
ImmPACT NovaRed (SK-4805) and Meyer’s hematoxylin counter stain were all from Vector 
Laboratories (Burlingame, CA). Samples were dehydrated and mounted with Permount solution 
(Fisher Scientific, Pittsburgh, PA). Images were acquired with a 10X 0.3 NA objective on 
Olympus BX-40 microscope with SPOT imaging software (Sterling Heights, MI). 
4.5.3 Immunostaining 
 Glass coverslips were coated with 2µg/cm2 Collagen I (BD Biosciences, Bedford, MA), 
Collagen + 2µg/cm2 Tenascin C (Millipore, Temecula, CA), Collagen + 2µg/cm2 Decorin (R&D 
Systems, Minneapolis, MN) in PBS for 12 hours at ambient temperature and then blocked for 30 
minutes with 0.1% BSA in PBS. Cells were seeded on coverslips and let attach 12h, and fixed 
with 4% formaldehyde for 115 min at ambient temperature. After washing with PBS, cells were 
treated for 5 min with 0.2% Triton-X, and stained with 568-Alexa-Fluor phalloidin (Molecular 
Probes, Invitrogen) and 2µg/ml DAPI (Sigma) for 40 minutes at ambient temperature. Images 
were acquired with an Olympus 60X 1.25 NA objective on the Olympus BX-40 microscope.    
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4.5.4 Confocal imaging of invasion into collagen gels 
Accellular collagen gels were made by mixing rat tail Collagen I (BD Biosciences, 
Bedford, MA) in NaHCO3-based buffer to a final concentration of 3mg/ml, as previously 
described (Simpson et al., 2010). TNC (Millipore, Temecula, CA), DCN (R&D systems, 
Minneapolis, MN) or both were added at a concentration of 4 µg/ml prior to the gel 
neutralization with 0.2M NaOH. 50µl gels were casted in optical clear cell culture inserts 
(353095, BD Falcon, Franklin Lakes, NJ).  5x104 WM1158 cells were seeded on top of the gels 
in 1% FBS medium and 10% FBS medium was added to the bottom of the insert to induce 
invasion. Gels were fixed after 72h and stained as described with modifications (Hooper et al. 
2006). Briefly, collagen inserts were washed with PBS, fixed 30 minutes in 4% formaldehyde-
0.25% glutaraldehyde in PBS, treated with 0.2% Triton X for 30 min on ice, and stained with 
0.2µg/ml 488-Alexa-Fluor phalloidin (Molecular Probes, Invitrogen) and 2µg/ml DAPI (Sigma) 
in dark for 3h. Gels were imaged directly in the inserts in PBS on the Nikon Sweptfield Confocal 
Microscope (TSI inverted) using 10X and 60X 1.4 NA objectives. 3D volume representations of 
Z-stacks were made using Nikon Elements software and surfaces of the invading cells were 
modeled with Imaris software based on the absolute intensity of phalloidin staining with 3µm 
surface area detail level (Bitplane, Zurich, Switzerland). Quantification of the depth of invasion 
was performed with the length measurement tool of Nikon Elements software by measuring 60 
random positions per sample from the surface of seeded cells to the bottom most detected 
intensity. Experiments were repeated three times. 
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4.5.5 Skin organ cultures and H&E staining 
Skin organ cultures were established as previously described (Grahovac et al., 2012; 
Simpson et al., 2010), with modifications. Briefly, 15x104 primary human fibroblasts were 
seeded in 1.5 ml 2mg/ml collagen gels alone or with the addition of 4µg/ml of TNC, DCN or 
both, in 24 well plates. After 5 days in submerged culture, 25x104 normal human keratinocytes 
were seeded on top of contracted gels. Keratinocytes were allowed to adhere and 48h later 
10x104 WM1158 cells were seeded in the center of the plug within the 4,7mm R cloning rings 
(Bel Art, 14-512-78, Thermo Fisher Scientific, Pittsburgh, PA), let attach for 8h and then the 
cloning rings were removed. After 3 days, the cultures were lifted to the air liquid interface to 
allow epidermis maturation and the medium was replenished every other day for total of 20 days 
of culture. The samples were fixed and paraffin embedded and H&E stained as previously 
described (Hood et al., 2010). The experiment was repeated two times with similar results. 
4.5.6 Statistical testing 
Statistical analysis in this study was performed by two-tailed Student's t test with a p < 
0.05 being required to be considered significant and values were shown as mean ± SD.  
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5.0  DISCUSSION  
 Despite the enormous efforts in developing new drug strategies to treat advanced 
melanoma, the number of melanoma related deaths rises yearly. Melanoma is one of the most 
aggressive and treatment-resistant human cancers. Given that there is a mathematical relationship 
between the primary tumor thickness and the survival prognosis (Balch et al., 2009) it appears 
that the invasive capacity that melanoma cells acquire at the primary tumor site greatly 
contributes to the disease outcome. Once the melanoma cells have penetrated the basement 
membrane and reached the dermis, they are very hard to combat. Therefore, an understanding of 
the events that lead to the progression from the radial epidermal melanoma spreading to the 
vertical invasion is crucial in order to design better treatment tactics. Many studies have 
concentrated on molecular changes that melanoma cells undergo during progression, and some 
of the recent therapies that target specific changes, like Vemurafenib - BRAF inhibitor that 
blocks V600E mutated BRAF, proved to be efficient. Nevertheless, the constant obstacle that is 
common for any type of cancer treatment is the acquisition of resistance to specific therapy and 
metastatic dormancy. It is postulated that the signals from the outside of the tumor cell shape the 
fate of disseminated tumor cells to progress or to pause in the state of dormancy (Ossowski and 
Aguirre-Ghiso, 2010). Moreover, since tumor microenvironment may also facilitate the 
development of multidrug resistance (Correia and Bissell, 2012), it is important to incorporate 
the knowledge on both tumor cells and their respective microenvironments in order to develop 
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the treatments of malignancies as complex organs rather than mutated cells. Targeting the 
microenvironment would, presumably, irrespective of the tumor cell heterogeneity, impede their 
survival and dissemination. In this work we investigated changes in the extracellular matrix of 
primary melanoma tumors to get a better understanding of how signaling from the extracellular 
space impacts melanoma cell invasion. 
5.1 SKIN ORGAN CULTURES AS A MODEL SYSTEM FOR STUDYING 
MELANOMA INVASION 
Given the microenvironmental complexity of primary melanoma, studies of melanoma 
cell behavior and drug response have to be undertaken in the models that resemble the natural 
occurrence most closely. Skin organ cultures are the most advanced in vitro system for this 
purpose, since they allow the incorporation and/or modification of the major cell types of the 
skin: keratinocytes, melanocytes, fibroblasts and melanoma cells.    
In this work we have first shown that melanoma cells incorporated into SOCs modify the 
extracellular matrix in the way that resembles melanoma microenvironment in human melanoma 
samples (Hood et al., 2010). Proteomic analysis of laser micro-dissected SOCs detected 
increased amounts of Tenascin C, Fibronectin and Thrombospondin-1 in melanoma seeded 
samples, matricellular proteins known to be involved in modulation of cell-matrix interactions 
(Fukunaga-Kalabis et al., 2008). Furthermore, we were able to detect a difference in the amounts 
of abundant intracellular proteins involved in cytoskeletal organization such as α-actinin-4 and 
plectin. The changes we detected in SOCs closely matched the changes detected by the 
proteomic analysis of the melanoma tissue sample and the uninvolved skin of a melanoma 
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patient. This proteomic approach shows promise in tracking protein changes in a high-
throughput manner in SOCs, compared to traditional immunostaining. For example, the response 
of the stroma to genetically manipulated melanoma cells and vice versa can be tracked by this 
approach or effects of therapy application on melanoma matrix composition. 
Next, we reasoned that by modifying the dermal compartment of SOCs, the influence of 
particular microenvironmental components on melanoma cell behavior could be followed. Based 
on the proteomic data from the patient sample, where significant upregulation of TNC and down-
regulation of DCN were detected, we included extra Tenascin C into dermal matrices of SOCs 
and observed an increased invasion of melanoma cells, or included Decorin and observed an 
inhibition of invasion. Decorin could also counteract invasion-promoting TNC in this setting. 
This proves that the composition of the ECM strongly impacts the ability of melanoma cells to 
disseminate from the primary site. 
5.2 HETEROGENEITY OF CANCER CELL MIGRATION PHENOTYPES IN THE 
MICROENVIRONMENTAL CONTEXT 
 The influence of the extracellular matrix on cancer invasion has long been recognized 
(Liotta, 1986). ECM protein TNC has been shown to promote cancer invasion by both MMP-
dependent and independent mechanisms (Hancox et al., 2009). TNC induces the expression of 
MMPs 1, 3, 9 and 13 (Hancox et al., 2009; Tremble et al., 1994) and the activation of MMP2, 
and there is a positive feedback loop between the induction of MMPs by TNC and its cleavage 
(Dang et al., 2004). Interestingly, cleavage sites for all the MMPs tested so far are outside of the 
EGFL repeats domain in the TNC molecule (Siri et al., 1995), leaving them intact in the face of 
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increased ECM remodeling. As the work from our group has previously shown that distinct 
EGFL repeats of TNC can promote pro-migratory EGFR signaling cascade (Iyer et al., 2008) we 
postulated that the increased TNC expression in melanoma allows increased migratory 
capabilities of cancer cells. Melanoma cells themselves secrete TNC (Herlyn et al., 1991), and 
we observed that the TNC production increases with an increase in severity of the stage from 
which the melanoma cells were derived and that the invasiveness in 3D matrices highly 
correlates with the amounts of TNC being deposited in the matrix (Grahovac et al., 2012). 
Imaging cells during their migration in three dimensions revealed that TNC is being deposited at 
the front of the invading cells.   
Given that TNC is a multidomain protein, signaling pathways that would promote 
invasive behavior are not obvious. We therefore over-expressed TNC EGFL repeats with the 
assembly domain in melanoma cells, and showed that they have profound effect on cell 
adhesion. Decreased adhesion was not due to changes in integrin expression, but due to increased 
activation of Rho–associated kinase (ROCK), which induced cytoskeletal reorganization and cell 
rounding due to contraction. As a result of decreased adhesiveness TNCEGFL-expressing cells 
moved slower on 2D substrates, but nevertheless moved faster and invaded deeper into 3D 
matrices, despite there being no increase in MMP activities. The persistence of cell invasion with 
low adhesion, high intracellular contractility and independence of MMP activity is a 
characteristic of amoeboid type of movement (Lammermann and Sixt, 2009; Sahai and Marshall, 
2003; Wolf et al., 2003). To our knowledge, this is the first signal from the extracellular matrix 
protein that has been shown to promote mesenchymal to amoeboidal migration switch. 
 The plasticity of the cell movement allows efficient migration in complex 
microenvironments and allows more effective cancer dissemination (Friedl and Wolf, 2003). It is 
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possible that a single cell during its invasion process can oscillate between mesenchymal and 
amoeboid modes of invasion, which are dictated by the microenvironmental signals, and cell 
mechanical properties. The initial invadopod-rich phenotype, which is needed for collagen 
invasion, can be switched to intracellular contractility-driven push through the space that has 
been released by the matrix-degrading enzymes. This phenotype could be time sensitive, e.g. 
change every couple of minutes/hours and highly dependent on the encountered ECM. While 
intracellular signaling pathways that control cell cytoskeleton during migration have been 
extensively studied, little is known about the signals from the outside of the cell that dictate the 
phenotypic switches in the migrational mode. Collagen fibril orientation has been shown to 
dictate the mesenchymal mode of migration (Provenzano et al., 2008), and we now show that 
EGFL repeats of TNC can induce cytoskeletal changes in melanoma cells that lead to a shift 
towards amoeboid movement. The expression of TNC not only modulates the structural 
composition of the ECM, but also permits greater migrational plasticity. We speculate that 
invadopod protrusions that can localize MMPs in the front of migrating cells (Yamaguchi, 2012) 
could cleave TNC (which we observed being deposited in the front) and TNCEGFL repeats 
could signal contraction and rounding of the cell body that then pushes forward. It is possible 
that after proteolytic cleavage, TNC fragments may have distinct signaling activity compared to 
the full-length TNC protein. Proposed mechanism by which TNC promotes melanoma cell 
invasion is depicted in Figure 28. These are further avenues of research that await exploration. 
Furthermore, it would be interesting to investigate whether TNC expression changes the stiffness 
of the ECM, as increased stiffness promotes transformation of epithelial cells (reviewed in 
(Kumar and Weaver, 2009)).  
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 Figure 28. Schematic representation of the proposed mechanism by which TNC 
promotes melanoma cell invasiveness.  
Having in mind plasticity of melanoma cell migration it would be interesting to 
investigate whether combinational therapy of MMP and ROCK inhibitors targeting both 
phenotypic modes could abolish melanoma cell migration.  
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5.3 DECORIN AS AN ANTI-INVASIVE MOIETY 
  
 We have found that TNC and DCN have inversed expression in melanoma and benign 
nevi samples. In melanoma TNC is up-regulated and DCN down-regulated, in contrast to benign 
nevi which have barely detectable TNC levels and prominent amounts of DCN. The expression 
of these two proteins is at least in part regulated by the same growth factor: TGFβ1 secreted by 
melanoma cells down-regulates DCN expression (Mauviel et al., 1995) and up-regulates TNC 
expression (Berking et al., 2001). These two proteins also have a common receptor – EGFR 
(Iozzo et al., 1999b; Iyer et al., 2007a), the signaling of which they dictate in opposite manner: 
DCN induces internalization and attenuation of EGFR (Zhu et al., 2005) while TNC promotes 
membrane-bound EGF pro-migratory cascades (Iyer et al., 2008). 
 Decorin possesses intrinsic potent anti-tumorigenic properties. It has a promiscuous 
binding repertoire consisting of ECM proteins, cell receptors and growth factors, and is 
considered to be a “guardian from the matrix” (Neill et al., 2012). Although previous studies did 
not find significant correlation between levels of DCN expression and Breslow tumor thickness 
or Clark level of melanoma (Brezillon et al., 2007; Gambichler et al., 2008) we found that 
primary melanoma samples contain decreased DCN amounts compared to benign nevi of the 
skin. Furthermore, we showed that DCN has a remarkable negative impact on melanoma cell 
invasion, in both simple collagen dermal equivalents and dermal equivalents enriched with 
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Tenascin C. Since DCN can inhibit TNC-induced melanoma invasion, we speculate that this 
inhibitory effect is signaled by inhibition of the EGFR signaling in response to TNC (Figure 29).  
 
 Figure 29. Decorin can counteract pro-invasive effects of TNC on melanoma cells.  
(A) Addition of DCN to dermal matrices ameliorates effects of TNC on melanoma 
invasion. (B) Possible mechanism by which DCN can counteract TNC. 
 
 EGFR gene undergoes frequent amplification in advanced melanoma (Koprowski et al., 
1985; Udart et al., 2001) and the gain of chromosome 7 copy number (on which EGFR gene 
resides) occurs later in the melanoma progression (Bastian et al., 1998). Despite the experimental 
evidence that EGFR can promote melanoma progression there is little clinical evidence that 
supports single agent anti EGFR therapy (Tsao et al., 2012). However, EGFR axis activation or 
over expression is a cause for resistance to Vemurafenib, one of the most effective drugs for 
treatment of melanoma that inhibits the oncopotein BRAF(V600E) (Prahallad et al., 2012). 
Therefore, the inhibition of EGFR in combinational therapy may be a candidate for future 
clinical investigations. Decorin could in this case contribute even more profoundly than chemical 
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EGFR inhibitors as it targets multiple kinase receptors involved in cancer promotion in addition 
to EGFR (Csordas et al., 2000; Iozzo and Sanderson, 2011). DCN gene delivery has already been 
shown to retard the growth of human tumors in immunocompromised animals (Reed et al., 2002) 
and due to its collagen binding capacity can even overcome the extracellular matrix barrier that 
is a major obstacle for successful adenoviral gene therapy (Choi et al., 2010). Therefore, Decorin 
is an excellent candidate for combinational therapy both as anti-tumor moiety itself, and as an 
enhancer of the distribution of targeted gene delivery.  
5.4 FUTURE DIRECTIONS 
 
This work has opened several new avenues of research. First, given the extent of 
knowledge on the composition of the melanoma microenvironment, systems for studying 
melanoma progression should be heterotypic and designed to mimic heterogeneity of both 
melanoma cells as well as the supporting stroma. Skin organ cultures could be further adapted to 
incorporate other cell types found in primary melanomas; such are endothelial cells and 
macrophages, as these were shown to have a significant role in cancer cell invasion. This model 
could also be customized to test the drugs that target tumor microenvironment. Second, we have 
shown that matrikine signaling can influence the mode of melanoma cell migration during the 
invasion. This plasticity of cell movement should be taken into account when considering 
melanoma treatment, as the two modes of cancer cell migration have different mechanistics and 
only the inhibition of both would potentially give results, e.g. a combination of MMP inhibitors 
and ROCK inhibitors. Finally, the ability of another ECM protein present in normal skin, to 
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counteract TNC should not be taken lightly. An exploration of the exact signaling mechanisms 
that DCN elicits to block melanoma cell invasion even in the presence of proinvasive TNC could 
shed light on potential regulatory nodes in cell pro-migratory molecular network that could be 
exploited for further drug development. 
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APPENDIX A 
COMPLETE LIST OF PEPTIDES IDENTIFIED IN MELANOMA AND SKIN TISSUE 
SAMPLES AND SOCS 
Appendix can be downloaded from http://pubs.acs.org/doi/full/10.1021/pr100164x 
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APPENDIX B 
B.1 ABBREVIATIONS 
 ACN-4 – α-actinin-4 
 ATP – adenosine thriphosphate 
 bFGF – basic fibroblast growth factor 
 BRAF – B rapidly accelerated fibrosarcoma kinase 
CAF – cancer-associated fibroblast 
Cdc42 – cell division cycle protein 42 
CGH – comparative genomic hybridization 
CK - cytokeratin 
COL - Collagen 
 CTLA-4 - cytotoxic T lymphocyte antigen-4 
DAPI - 4',6-diamidino-2-phenylindole 
DCN - Decorin 
 E-cadherin - epithelial cadherin 
ECM – extracellular matrix 
EGF- epidermal growth factor 
EGFR – epidermal growth factor receptor 
FBS – fetal bovine serum 
FDA -Food and Drug Administration 
FFPE – formalin-fixed paraffin-embedded 
FN - Fibronectin 
FNIII – Fibronectin III like 
GAPDH – glyceraldehide-3-phosphate dehydrogenase 
GTP – guanosine thriphosphate 
IGF-1R – insulin-like growth factor 1 receptor 
LTQ – linear trap quadrupole 
Met receptor – mesenchymal epithelial transition receptor 
MGP - metastatic growth phase 
MLC – myosin light chain 
MMP – matrix metallo-protease/proteinase 
MS – mass spectrometry 
MYPT – myosin phosphatase targeting protein 
NA – numerical aperture 
N-cadherin - neural cadherin 
PDGF – platelet-derived growth factor 
PLA – proximity ligation assay 
Rac – Ras-related C3 botulinum toxin substrate 
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Ras – Rat sarcoma oncogene 
Rho – Ras homolog  
RGP - radial growth phase 
ROCK – Rho associated kinase 
SAGE – serial analysis of gene expression 
SD – standard deviation 
SEM – standard error mean 
SOC – skin organ culture 
SPARC – secreted protein acidic rich in cysteine 
TGF-β – tumor growth factor β 
TLR4 – toll like receptor 4 
TMA – tissue micro array 
TNC – Tenascin C 
TNFα – tumor necrosis factor α 
TSP-1 – Thrombospondin-1 
VGP - vertical growth phase 
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